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 ZUSAMMENFASSUNG 
Der Humane T-Zell Leukämie-Virus-Typ 1 (HTLV-1) ist ein Retrovirus, der neben 
anderen Krankheiten auch die Akute T-Zell Leukämie (ATL) hervorruft. Aufgrund der 
Apoptose-Resistenz HTLV-1 infizierter T-Zellen kann mit bisherigen Therapien ATL nur 
unzureichend behandelt werden. 
Die erhöhte Expression anti-apoptotischer Proteine, die in der Modulation des 
intrinsischen Signalwegs der Apoptose beteiligt sind, wurde als ein Mechanismus der 
Apoptose-Resistenz postuliert. 
In vorangegangenen Arbeiten konnten wir zeigen, dass HTLV-1-infizierte T-Zellen im 
Vergleich zu nicht-infizierten Zellen eine höhere Resistenz  gegenüber sowohl CD95L- 
als auch TRAIL-induzierter Apoptose aufweisen. Dies deutet auf einen gemeinsamen 
Mechanismus der Resistenz gegenüber Todesrezeptor-vermittelter Apoptose hin. Vor 
kurzem konnte unsere Gruppe weiterhin zeigen, dass der extrinsische Signalweg der 
Apoptose in HTLV-1-infizierten T-Zellen durch erhöhte Expression von c-FLIP blockiert 
ist. Durch Kompetition mit Procaspase-8 um die Bindungsstellen von FADD bei der 
Bildung des DISC-Komplexes inhibiert c-FLIP die Todesrezeptor-vermittelte Apoptose. 
Zur Überwindung der Resistenz wurden HTLV-1-infizierte T-Zellen mit CD95L bzw. 
TRAIL allein oder in Kombination mit Rocaglamide behandelt. Rocaglamide ist ein 
pflanzlicher Inhaltsstoff, der Anwendung in der traditionellen chinesischen Medizin 
(TCM) findet. Wir konnten zeigen, dass ein aktives Rocaglamide-Derivat (Roc-AR) 
HTLV-1-infizierte T-Zellen durch Reduktion der c-FLIP-Expression auf 
posttranskriptionaler Ebene gegenüber CD95L- und TRAIL-vermittelter Apoptose 
sensitiviert. Weitere Untersuchungen ergaben, dass der von Roc-AR-vermittelte 
Mechanismus der Inhibition der Translation sich von den Mechanismen anderer 
Inhibitoren der Translation unterscheidet: Roc-AR hemmt den Ras-
Signaltransduktionsweg, was wiederum eine Hemmung von Mnk-1, einer Proteinkinase, 
die den eukaryotischen Initiationsfaktors der Translation 4E (eIF4E) aktiviert, hervorruft. 
Die Roc-AR-vermittelte Blockade der Aktivierung von eIF-4E hemmt die cap-abhängige 
eukaryotische Translation in der Phase der Initiation der Translation. Im Gegensatz 
dazu hat Roc-AR keinen Einfluss auf die CD95L- und TRAIL-induzierte Apoptose 
peripherer nicht-infizierter T-Zellen. Durch die spezifische Sensitivierung infizierter 
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 Zellen durch Roc-AR besteht die Möglichkeit, Roc-AR in Kombination mit CD95L- bzw. 
TRAIL zur Therapie von ATL und anderer Arten von T-Zell-Tumoren einzusetzen. 
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 ABSTRACT  
Human T cell Leukemia Virus Type 1 (HTLV-1) is a retrovirus, associated with several 
diseases including Adult T-cell Leukemia/Lymphoma (ATL). Because of apoptosis 
resistance treatment provides only limited benefits for ATL.  
CD95/CD95L-mediated apoptosis is an important mechanism of T cell homeostasis. We 
have previously shown that HTLV-1 infected T cells are more resistant to CD95L-
induced apoptosis as compared to non HTLV-1 infected T cells. In this study we showed 
that HTLV-1 infected T cells are also resistant towards TRAIL, which suggests a general 
mechanism of resistance towards death receptor-mediated apoptosis.  
The basis of apoptotic resistance in HTLV-1 infected T cells was suggested to be due to 
the elevated expression of several anti-apoptotic proteins involved in modulation of the 
intrinsic cell death pathway. Recently our group further found that apoptosis is also 
blocked within the extrinsic cell death pathway by high c-FLIP expression. C-FLIP is an 
anti-apoptotic protein that blocks death receptor-mediated apoptosis at the DISC level. 
To overcome resistance, we have treated HTLV-1 infected T cells with CD95L or TRAIL 
in combination with an herbal compound, Rocaglamide, derived from a Traditional 
Chinese Medicinal plant (TCM). We showed that one of the Rocaglamide derivatives 
tested, Roc-AR, sensitizes HTLV-1 infected T cells towards CD95L- and TRAIL-
mediated apoptosis via down-regulation of c-FLIP expression at the translational level. 
Further investigation of the molecular mechanisms by which Roc-AR suppresses c-FLIP 
translation, revealed a mechanism different from other known translation inhibitors. Roc-
AR strongly inhibits the Ras pathway leading to the inhibition of Mnk-1, a protein kinase 
essential for the activation of the translation initiation factor 4E (eIF4E). Thus, blocking 
activation of eIF4E by Roc-AR leads to inhibition of cap-dependent eukaryotic 
translation at the initiation stage. Most importantly, Roc-AR does not sensitize normal 
peripheral blood T cells to CD95L-and TRAIL-induced apoptosis. Our study raises the 
possibility to develop Roc-AR as CD95L or TRAIL adjuvant for treatment of ATL and 
other types of T-cell tumors.  
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Introduction 
1 INTRODUCTION 
1.1 Introduction to HTLV-1 
Human T Cell Leukemia Virus (HTLV) is a type C retrovirus and is the first human 
oncogenic retrovirus identified. It was isolated from a cell line derived from a patient with 
cutaneous T-cell lymphoma (Poiesz et al., 1980). Independently, a related retrovirus was 
isolated from another patient with adult T-cell leukemia/lymphoma (ATL) and was 
described as Adult T-cell Leukemia Virus (ATLV) (Yoshida et al., 1982). HTLV and ATLV 
were later demonstrated to be the same retrovirus based on homology between the viral 
genome and viral antigens. This retrovirus was renamed HTLV-1 (Watanabe et al., 
1984).  
HTLV-1 has infected ~ 15-20 million people worldwide and is endemic in Southwest 
Japan, the Caribbean islands, southeastern parts of USA and parts of Central and South 
Africa (De The et al., 1993; Edlich et al., 2000). HTLV-1 infects various cell types 
including CD8+ T cells, B cells, dendritic cells and fibroblasts. However, the HTLV-1 
provirus is predominately found in CD4+ T cells (Hanon et al., 2000; Yasunaga et al., 
2001). Most viruses are spread by causing the infected cell to release thousands of virus 
particles. In contrast, HTLV-1 needs cell to cell contact for transmission,  which takes 
place upon forming of a virological synapse between an infected and non-infected cell 
(Nejmeddine et al., 2005). It is thought that this is partly mediated by the interaction 
between the Glucose-transporter GLUT-1 on the non-infected cell and the envelope 
protein (Env) on the infected cell (Manel et al., 2003).  
HTLV-1 infected cells enter the human body via three major routes, namely transmission 
from mother to child through breast feeding, sexual transmission and parenteral 
transmission through infected blood, blood components or by infected needles (Tajima, 
1988; Chen et al., 1989). Besides these routes, transplacental transfer has also been 
reported (Komuro et al., 1983).  
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1.2 HTLV-1 genomic structure and Tax protein 
The size of the HTLV-1 genome is ~ 9 kb. It is comprised out of two copies of a single-
stranded RNA. The genome is reverse transcribed into a double-stranded DNA that 
integrates into the host cell genome referred to as provirus. The HTLV-1 provirus 
includes, like other retroviruses, Gag, Pol, and Env genes encoding the viral matrix, the 
capsid, and envelope proteins, as well as enzymes such as reverse transcriptase and 
integrase (Seiki et al., 1983). In addition, the HTLV-1 genome encodes for several 
regulatory and accessory proteins via alternative splicing and an internal initiation codon 
located between the Env gene and the 3’-end of the genome (Fig. 1.1). The region 
encoding these proteins is called the pX region (Seiki et al., 1983).  
 
Gag Pol Env pX5’ LTR 3’ LTR
HTLV-1 provirus 
genome
ORF-I
ORF-II
ORF-III
ORF-IV
ORF-II = p30 + p13
ORF-I = p12 
ORF-III = Rex + p21
ORF-IV = Tax
 
Figure 1.1: Genomic organization of HTLV-1 
The HTLV-1 provirus genome encodes for Gag, Pol, and Env genes. In addition, the 
HTLV-1 genome contains a pX region, which contains four partially overlapping open 
reading frames (ORF), X-I – X-IV, encoding for several regulatory and accessory 
proteins. ORF-IV encodes for the Tax protein, which is considered as the major player 
involved in transformation events of HTLV-1 infection. 
 
The pX region consists of four partially overlapping open reading frames (ORF),      
ORF-I – IV. ORF-I and II encode for the accessory proteins p12, p13 and p30 which 
have a role in transcriptional regulation, viral persistence and virus assembly (Albrecht 
and Lairmore, 2002). ORF-III codes for the Rex protein which is necessary for the export 
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of unspliced viral RNA from the nucleus (Heger et al., 1999) and codes as well for p21, a 
protein of unknown function. ORF-IV encodes the Tax protein which is thought to be the 
major player in transformation events of HTLV-1 infection (Felber et al., 1985).  
Tax is a 40 kDa (353 amino acids) protein which is predominantly located in the nucleus 
of the host cell. Tax induces cell immortalization and transformation in vitro (Grassmann 
et al., 1989; Pozzatti et al., 1990; Grassmann et al., 1992) as well as tumor formation in 
transgenic mice (Nerenberg et al., 1987). Tax was initially identified as a trans-acting 
transcriptional activator of the HTLV-1 promoter in the LTR (Felber et al., 1985; Seiki et 
al., 1986; Sodroski et al., 1985), later it was shown that Tax can also trans-activate 
transcription of various cellular genes. 
1.3  HTLV-1 associated diseases 
HTLV-1 infection can lead to the development of Adult T Cell Leukaemia/Lymphoma 
(ATL), a malignancy of the clonal proliferation of infected mature CD4+ T cells (Yoshida 
et al., 1982). The infected malignant CD4+ T cells have characteristic large, irregular 
nuclei, called ‘leukemic flower cells’. The clinical course of ATL is progressive and can 
be divided into four clinical stages: pre-ATL, smoldering, chronic and acute ATL.  
The chronic and smoldering stages of the disease have an indolent early course but 
progress to the acute form after a variable period of time (Shimoyama, 1991). During the 
acute stage of ATL, a tumor burden is observed, including massive lymphadenopathy, 
hepatosplenomegaly, infiltrative skin lesions, central nervous lesions and hypercalcemia 
(Watanabe et al., 1990). Only 2-4% of the carriers develop ATL which starts after a 
latent time of 20 to 40 years after infection (Yamaguchi, 1994). Besides ATL, HTLV-1 
infection was also found to cause the neurological disease: tropical spastic paraparesis 
(TSP) (Gessain et al., 1985) and HTLV-1-associated myelopathy (HAM), later identified 
to be identical myelopathies (TSP/HAM) (Osame et al., 1986). TSP/HAM is a chronic, 
progressive neurological disease characterized by degeneration of the spinal cord and 
the presence of infiltrating T cells in both peripheral blood and cerebrospinal fluid. 
Patients have high levels of circulating HTLV-1-specific CD8+ cytotoxic T cells which 
mainly recognize the same epitope of the HTLV-1 Tax protein (Tax 11-19) (Bangham, 
2000; Mosley et al., 2005). Furthermore, HTLV-1 infection indirectly causes other 
 
14
Introduction 
diseases via induction of immunodeficiency, such as chronic lung diseases and infection 
with strongyloides stercoralis (Porto et al., 2001; Carvalho and Porto, 2004). HTLV-1 is 
also associated with diseases, such as uveitis, which involves the inflammation of the 
eye and Sjogren syndrome, an autoimmune disorder in which immune cells attack and 
destroy the glands that produce tears and saliva (Terada et al., 1994; Mochizuki et al., 
1992; Nishioka et al., 1989). 
1.4  HTLV-1 persistence 
HTLV-1 has been shown to activate and immortalize human T cells in vitro, although the 
exact mechanisms are still not fully understood (Gazzolo et al., 1987; Kimata et al., 
1991). HTLV-1 transformation appeared to be a multi-step oncogenic process in which 
HTLV-1 infection represents the first event (Franchini, 1995). Shortly after infection the 
virus enters a latent state, rendering the infected individuals asymptomatic seropositive 
healthy carriers. During this latency period the viral gene expression in the infected 
peripheral CD4+ cells is very low (Richardson et al., 1997). Also, very low levels of viral 
proteins are detectable in the infected cells (Kinoshita et al., 1989). It has been thought 
that antibody responses against viral antigens and HTLV-1-specific CD8+ cytotoxic T 
cells might be important immune effectors that suppress the outgrowth of HTLV-1-
transformed T cells and thus, reduce the risk of ATL development in healthy carriers 
(Mitsuyu et al., 1983; Jacobson et al., 1990; Kannagi et al., 2005). It was shown that 
infected CD4+ T cells isolated from healthy carriers started to produce high viral gene 
expression when cultured in vitro (Asquith et al., 2000; Tochikura et al., 1985; Hanon et 
al., 2000). Addition of sera from the carrier into the culture medium inhibited viral 
expression whereas sera of uninfected control donors did not (Tochikura et al., 1985). 
Depletion of antibodies from the sera abolished this inhibition. It was also shown that the 
amount of infected CD4+ T cells increased after HTLV-1-specific CD8+ cytotoxic T cells 
had been depleted from the blood samples. Therefore, the viral load in HTLV-1 infected 
individuals could increase during the latency time primarily by proliferation of the proviral 
DNA-harboring cells rather than by repeated cycles of cell to cell infection of new 
uninfected cells (Etoh et al., 1997).  Since ATL develops only in 2-4% of the people 
infected with HTLV-1 after a long latent period, it is possible that the virus infected T 
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cells are not killed by HTLV-1-specific CD8+ cytotoxic T cells in a subpopulation of 
HTLV-1 carriers with a specific immunogenetic background (Uzuku et al., 1988; Sonoda 
et al., 1996). Recent studies have found that the frequency, diversity and function of 
HTLV-1-specific CD8+ cytotoxic T cells are reduced in ATL patients as compared to 
healthy donors (Kozako et al., 2006). Furthermore, in TSP/HAM patients, a strong 
increase in the viral load is found as compared to healthy donors. The increase in the 
viral load was mainly dependent on the ‘efficiency’ of their HTLV-1-specific CD8+ 
cytotoxic T cells (Bangham 2003; Vine et al 2004; Asquith et al 2005). CD8+ cytotoxic T 
cells kill virus infected cell mainly by two mechanisms namely by the CD95 system 
mediated by CD95L on their surface or by the perforin/granzyme B system. Activation of 
CD95 or the entry of Granzyme B in the virus infected cell leads to the cleavage and 
activation of caspases and cell death. Accumulating evidence shows that HTLV-1 
infected T cells are resistant towards CD95-induced apoptosis (Copeland et al., 1994). 
The survival mechanisms of HTLV-1 infected cells are poorly understood. It is widely 
believed that modulation of cell proliferation and resistance towards apoptosis play both 
a major role in persistence of HTLV-1 infection and disease development. 
1.5.1 Introduction to the cell cycle  
The cell cycle describes the process of cell duplication. It is the basis for the 
reproduction and sustained growth of all living organisms. Whether cells progress 
through the cell cycle or not, depends to a large extent on presense of growth factors. 
The eukaryotic cell cycle is divided into four phases namely the G1, S, G2 and M phase 
(Fig.1.1). In addition to these cell cycle phases, the term G0 phase is used to describe 
cells that have exited the cell cycle and become quiescent. The cell cycle regulation is 
tightly controlled by cyclins and the cyclin dependent kinases (CDKs) (Kato, 1999). 
Cyclins are activating subunits of CDKs that interact with their specific CDKs and 
regulate their activity. The first cyclin-CDK complex activated during the G1-phase is 
composed of D-type cyclins in association with CDK4 or CDK6. 
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Figure 1.1: Cell cycle and cyclin dependent kinases (CDKs). 
The G1 phase is the phase when the cell becomes committed to DNA replication and the 
decision on entering cell cycle is made (Hartwell et al., 1974; Nurse, 1975). During the S 
phase DNA synthesis occurs and during the G2 phase the cell prepares for the process 
of division. The phase in which the replicated chromosomes are segregated into 
separate nuclei is called mitosis (M-phase). In this phase, the cell divides into two 
daughter cells.  
 
As cells progress through the G1 phase, cyclin E is expressed and associates with 
CDK2, which is essential for entry in the S phase. In the S phase, cyclin E is degraded 
and CDK2 associates with cyclin A. Finally, cyclin A and B associate with CDK1 and 
promote entry into mitosis. In G0 cells, the levels of D-type cyclins (D1, D2, and D3) are 
controlled at several levels like transcription, translation and protein stability. Stimulation 
of cells with growth factors leads to the transcription of D-type cyclins via the signal 
transduction pathways ERK and PI3K-Akt (Cheng et al., 1998; Klippel et al., 1998, 
Pouyssequr et al., 2007).  
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1.5.2 Regulation of the cell cycle  
The cell cycle is not only regulated at the transcriptional level but can also be regulated 
directly on the translational level (Proud and Averous, 2006). Protein translation is 
considered as a three-stage process, consisting of an initiation, elongation and 
termination phase (Feliers et al., 2006). Protein translation is tightly regulated, 
predominantly at the level of initiation by the modification of the eukaryotic initiation 
factors (eIFs) (Sonenberg and Frederickson, 1992).  
In eukaryotes, most mRNAs are translated in a cap-dependent manner. The cap 
structure, m7GpppN (where N is any nucleotide), is present at the 5’ terminus of all 
cellular eukaryotic mRNAs. The mRNA 5' cap structure is recognized and bound by the 
translation initiation factor eIF4E. After binding to the 5’ cap structure, eIF4E interacts 
with eIF4G, which serves as a scaffold protein for the assembly of eIF4E and eIF4A to 
form the eIF4F complex. The eIF-4F complex is directed to the 5’ terminus of the mRNA 
and unwinds the mRNA 5’ secondary structure to facilitate ribosome binding which 
promotes ribosome recruitment and translation (Gingras et al., 1999b). 
An alternative mechanism for the recruitment of ribosomes to mRNA is the so called 
internal ribosome binding (Jackson, 1995). This process, which is mediated by the direct 
binding of the ribosome to an Internal Ribosome Entry Side (IRES) bypassing the 5’ cap, 
was first reported for picornaviral mRNAs (Sonenberg, 1996). Viral IRES-dependent 
translation is efficient even when host cell cap-dependent translation is inhibited. This is 
mediated via the tertiary structure of the IRES, which is in turn stabilized by binding to 
cellular factors which interact directly with the translational machinery (Le and Maizel, 
1997).  
As mentioned, in eukaryotes, most mRNAs are translated in a cap-dependent manner 
by binding of the translation initiation factor eIF4E. The amount of the translation 
initiation factor eIF4E is limited as compared with other initiation factors and is therefore 
an important target for translational regulation (Duncan et al., 1987; Sonenberg, 1996). 
The activity of eIF4E is regulated by several mechanisms. At the transcriptional level, 
eIF4E mRNA levels are increased in response to growth factors. Second, the assembly 
of the eIF4F complex is inhibited by the translational repressor of eIF4E-binding proteins 
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(4E-BP1). In their hypophosphorylated state, they interact with eIF4E and prevent the 
recognition and binding to the 5’ cap structure. Upon phosphorylation, the interaction 
between 4E-BP1 and eIF4E disrupts, allowing eIF4E to bind to the 5’cap structure and 
assemble the translation initiation complex. 4E-BP1 is phosphorylated by the kinase 
mTOR (molecular target of rapamycin), which, in turn is activated upon stimulation with 
growth factors by the PI3K/Akt pathway (Fig. 1.2). Rapamycin treatment inhibits mTOR 
activation and thereby inhibits 4E-BP1 phosphorylation. This increases the interaction 
between eIF4E and 4E-BP, and consequently inhibits cap-dependent translation. 
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Figure 1.2: The intracellular signaling pathways regulating translation.  
The activity of eIF4E is regulated by several pathways. The activation the PI3K/AKT 
pathway leads to the phosphorylation of 4E-BP1 mediated by the kinase mTOR. The 
growth factor induced ERK pathway and the stress-induced p38 MAPK pathway 
phosphorylate the kinase Mnk1 which in turn phosphorylates the initiation factor eIF4E. 
Phosphorylation of eIF4E increases its affinity for the 5’ cap structure and thereby 
initiates translation. 
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The phosphorylation state of S209 correlates with the translation rate and growth status 
of the cell (Kleijn et al., 1998). Phosphorylation of eIF4E has been thought to increase its 
affinity for the 5’ cap structure and thereby stimulates translation. As increased 
phosphorylation of eIF4E was found in Ras-transformed cells (Rinker-Schaeffer et al., 
1992), an important role has been suggested for the Ras/Raf/ERK pathway. The 
activation of the ERK signaling pathway and thereby the phosphorylation of eIF4E 
occurs by a variety of extracellular stimuli such as hormones, cytokines or growth factors 
(Flynn and Proud, 1997; Wang et al., 1998). Also the p38 MAPK pathway is known to 
phosphorylate eIF4E (Wang et al., 1998). This pathway is induced by cellular stress, 
including heat shock, UV irradiation or anisomycin treatment (Waskiewicz and Cooper 
1995; Kyriakis and Avruch, 1996). Induction of phosphorylation of eIF4E by anisomycin 
is prevented by the p38 MAPK inhibitor SB203580 (Morley and Mckendrick, 1997; Wang 
et al., 1998). It has been demonstrated that the phosphorylation of eIF4E by the mitogen 
induced ERK pathway and the stress induced p38 MAPK pathway converge on the 
eIF4E kinase Mnk1 (MAP kinase interacting kinase 1). Stimulation of either pathway 
resulted in Mnk1 phosphorylation and subsequent activation (Fukunaga et al., 1997; 
Waskiewicz et al., 1997). Mnk1 was found to efficiently phosphorylate eIF4E in vitro, and 
appeared to be the candidate to phosphorylate eIF4E after stimulation of one of the two 
pathways. Translational control has important implications for cell growth, cell survival 
and apoptosis. eIF4E plays an important role in the regulation of cell cycle progression, 
particularly in the G1/S progression by increasing the levels of cyclin D1 and D2 (Tan et 
al., 2000). eIF4E can also rescue cells from apoptosis, by inhibiting mitochondrial 
cytochrome c release through an increase in Bcl-XL mRNA translation (Li et al., 2003). 
Synthesis of proteins that regulate cell proliferation can alter the balance between cell 
survival and cell death. eIF4E plays a key role in the control of this balance by regulating 
protein translation. This balance is disturbed in a variety of cancers overexpressing 
eIF4E, including breast, lung, prostate, cervix, Hodgkin’s lymphma and colon cancer  
(Tan et al., 2000; Clemens, 2001; Dua et al., 2001; Li et al., 2003). Inhibitors of the 
pathways controlling eIF4E and thus cap-dependent translation are therefore promising 
therapeutic targets for the treatment of cancer. 
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1.5.3 Modulation of cell cycle by Tax   
Tax expressing cells display an accelerated progression at the G1-phase (Lemoine et 
al., 2001). Several different mechanisms have been proposed to explain the accelerated 
progression of the G1-phase in Tax-expressing cells. First, studies have shown that 
signaling pathways are activated in HTLV-1 infected T cells. In HTLV-transformed Rat-1 
cells, the PI3K-Akt pathway was found to be constitutively activated and to be involved 
in cell transformation (Jeong et al., 2005; Liu et al., 2001). Currently, it remains unclear 
how Tax stimulates this pathway. The ERK-JNK cascade has also been shown to be 
constitutively activated in Tax-transformed murine fibroblasts, in human lymphocytes 
transformed in vitro by HTLV-1, and in leukocytes isolated from ATL patients. However, 
this activation is not induced by Tax alone (Xu et al., 1996).  
Second, it has been shown that Tax induces cyclin D2 expression (Santiago et al., 
1999). The increased cyclin D2 expression also coincides with expansion of cyclin D2 
binding partners Cdk4/6 (Santiago et al., 1999; Huang et al., 2001). Third, Tax may 
directly bind to cyclin D2 and stabilize the cyclin D/Cdk4 complex (Haller et al., 2002). 
Additionally, Tax may also directly bind to CDK inhibitor (CDKI) p16INK4A, thereby 
preventing it from binding to Cdk4 and Cdk6 (Low et al., 1997). Taken together, Tax is 
able to generate an abundance of activated cyclin D/Cdk complexes, and promote G1- to 
S-phase transition and cell proliferation. 
1.6.1  Introduction to Apoptosis 
Development and maintenance of a multicellular organism does not only require cell 
proliferation but also a balance of proliferation and cell death. Already in 1842, Carl Vogt 
described that cells can die in a regulated process (Vogt et al., 1842), an observation 
later on also found to be involved in embryogenesis (Gluecksmann et al., 1951). This 
regulated process of death was called programmed cell death. Later on, the term 
'apoptosis' was proposed by Kerr, Wyllie and Currie in 1972 to describe the 
morphological processes of controlled cellular self-destruction. (Kerr et al., 1972). The 
word ‘apoptosis’ is of Greek origin and describes the process of leaves falling from trees. 
This implies that death is an active and defined process of the life cycle of an organism. 
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The apoptotic form of cell death is essential for regulation of development, differentiation 
and maintenance of cell populations in tissues, especially in the immune system 
(Krammer, 2000; Los et al., 1999; Vaux and Korsmeyer., 1999). On the one side, failure 
in the apoptotic process may result in autoimmune diseases, cancer and spreading of 
viral infections (Thompson, 1995). On the other side, excessive apoptosis has been 
associated with other diseases, such as AIDS and several neurodegenerative disorders 
(Cacabelos et al., 1996). A cell undergoing apoptosis shows characteristic biochemical 
and morphological changes. In an early stage of apoptosis, the cell shrinks and looses 
contact with neighbouring cells followed by chromatin condensation and plasma 
membrane blebbing. Finally the cell is fragmented into closed membrane structures, 
which are called ‘apoptotic bodies’ containing the cytosol, the condensed chromatin and 
organelles. These events are the result of the activation of proteolytic enzymes that 
mediate the cleavage of a multitude of specific protein substrates which are normally 
important in the integrity and shape of the cell and its organelles. Further on, these 
enzymes lead to the cleavage of DNA into oligonucleosomal fragments in approximately 
180 to 200 bp fragments, which can be visualized by the typical ‘DNA ladder’ formation, 
seen after separation in an agarose gel (Wyllie et al.,1980; Steller et al., 1995). The 
apoptotic form of cell death is different from necrosis (Fig. 1.3). Necrosis occurs in 
response to a major insult as injury by toxins, or ischemia. Necrosis shows cell swelling, 
eventually the destruction of the cellular organelles, rupture of the plasma membrane 
and finally leakage of the cellular content into the cellular environment. Often, necrotic 
cell death is associated with damage of surrounding cells and a strong inflammatory 
response in the corresponding tissue (Okada et al., 2004).  
Apoptosis lead to the activation of a family of cysteinyl proteases, called caspases 
(cysteinyl aspartate-specific protease). The caspases are synthesized as non-active 
zymogens, procaspases, and upon activation cleavage of substrates occurs on the 
carboxyl-side of an aspartate residue (Cohen, 1997; Stennicke, 1998; Thornberry, 
1998). Upon death signals, the caspases are proteolytically processed, generating a 
heterotetramer consisting of each two small and two large subunits. There are 14 
mammalian caspases identified which can be grouped into two subclasses involved in 
apoptosis. The first subclass contains the initiator caspase-8, -9 and -10. These 
caspases contain either a death effector domain (DED) or a caspase recruitment domain 
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(CARD) (Hoffmann, 1997). The DED is found in caspase-8 and -10 and is necessary for 
interaction of these caspases with the adaptor protein FADD (FAS associated protein 
with death domain). The CARD domain found in caspase-9 is involved in promoting 
interactions with other caspases and with other regulatory proteins such as APAF-1. The 
second subclass of caspases is the effector or executioner caspases, including   
caspase-3, -6 and -7. These caspases cleave several cellular substrates, ultimately 
leading to the typical apoptotic morphology of the cell (Muzio et al., 1998). The anti-
apoptotic proteins of the IAP family (inhibitors of apoptotic proteins) can directly inhibit 
caspase activity. The IAP family proteins, including XIAP, cIAPs and survinin, bind 
specifically to the effector caspase-3 (Roy et al., 1997). In this way they can inhibit its 
proteolytic activation. 
Caspases can be induced by external or internal stimuli by the induction of two major 
pathways, namely the death receptor (extrinsic) cell death pathway and the 
mitochondrial (intrinsic) cell death pathway. 
 
necrosis apoptosis
life cell
 
 
Figure 1.3: Hallmarks of the apoptotic and necrotic cell death process. 
Apoptosis involves cellular shrinking, chromatin condensation, plasma membrane 
blebbing and formation of membrane-bound ‘apoptotic bodies’, which are phagocitized 
without triggering inflammatory processes. The necrotic cell death is characterized by 
swelling, plasma membrane rupture and release of its content into the surrounding tissue 
resulting in inflammation. 
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1.6.2  The death receptor (extrinsic) cell death 
pathway  
The tumor necrosis factor receptor (TNF-R) superfamily regulates a large number of 
biological functions, such as growth, differentiation and apoptosis (Locksley et al., 2001). 
The extracellular ligand binding sites of these receptors are characterized by a number 
of cysteine rich domains which are necessary for specific ligand recognition (Naismith 
and Sprang, 1998). Death receptors (DR) belong to a subfamily of the TNF-R 
superfamily (Fig. 1.4). Until now, six members of the subfamily of death receptors have 
been characterized: tumor necrosis factor receptor 1 TNF-R1 (DR1, CD120a), CD95 
(DR2, APO-1, Fas), DR3 (APO-3, LARD, TRAMP, WSL1), TNF-related apoptosis-
inducing ligand receptor 1 (TRAIL-R1, DR4, APO-2), TRAIL-R2 (DR5, KILLER, TRICK2) 
and DR6 (ectodysplasin) (Schulze-Osthoff et al., 1998; Ashkenazi and Dixit, 1999; Zola 
et al., 2005). Death receptors differ from the other TNF-R members by a common 
cytoplasmic conserved sequence of 80 amino acids, called death domain (DD), which is 
important for the transduction of the apoptotic signal (Itoh et al., 1993; Tartaglia et al., 
1993). CD95 (APO-1/FAS) is one of the most studied death receptors and was 
discovered by the generation of monoclonal antibodies which induced apoptosis in 
various human cell lines (Trauth et al., 1989; Yonehara et al., 1989). CD95 is a type I 
transmembrane glycoprotein with a molecular mass of approximately 45 to 52 kDa (Itoh 
et al., 1991; Oehm et al., 1992). CD95 is expressed in many tissues and cells, mostly in 
thymus, heart, lung and liver. Under normal physiological conditions CD95-mediated 
apoptosis is triggered by its natural ligand, CD95L (APO-1L/CD178).  
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Figure 1.4: Death receptors, decoy receptors and their ligands.  
Members of the subfamily of death receptors are characterized by cysteine rich domains 
(yellow squares) and a cytoplasmic conserved death domain (DD) (red). Death receptors 
are shown using a gray background. 
 
CD95L is a type II membrane protein of the TNF family with a molecular mass of 40 kDa 
(Suda et al., 1993; Takahashi et al., 1994; Yu et al., 1999). In contrast to the widespread 
expression of CD95, CD95L expression is restricted to the immune system, mainly to 
CD4+, CD8+ and natural killer (NK) cells and a few tissues including the immune-
privileged areas such as the iris (Griffith et al., 1995). CD95L is also expressed in 
several types of tumor cell lines (O’Connell et al., 1996; Strand et al., 1996). Expression 
of CD95L can be induced in T cells through activation of the T cell receptor. CD95L 
exists in a membrane-bound as well as in a soluble form. The soluble form of CD95L is 
generated from cleavage of the transmembrane form by metalloproteases (Kayagaki et 
al., 1995; Mariani et al., 1995; Tanaka et al., 1998). Besides it’s ligand, CD95-mediated 
apoptosis can also be induced by agonistic antibodies (Trauth et al., 1989).  
The CD95 system plays an important function in maintaining homeostasis in the immune 
system by inducing apoptosis in T cells, and eliminating auto-reactive lymphocytes in the 
periphery. Mice lacking functional CD95 (lpr/lpr) (lymphoproliferation) show the 
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phenotype of the autoimmune disease lupus. Similar to lpr-/- mice, mice lacking 
functional CD95L (gld/gld) (generalized lymphoproliferative diseases) fail to 
appropriately remove autoreactive lymphocytes from their immune systems (van Parijs 
and Abbas, 1996). In humans a similar disease with a dysfunction of the CD95 system is 
found called autoimmune lymphoproliferative syndrome (ALPS). These patients show 
massive, non-malignant lymphadenopathy, an altered and enlarged T-cell population 
and severe autoimmunity (Lenardo, 2003).  
Besides CD95, also other death receptors play an important role in the immune system. 
TRAIL-R1 and R2 are activated by their ligand TRAIL (TNF-related apoptosis-inducing 
ligand). Besides TRAIL-R1 and R2, many cells also express the decoy receptors Dc-R1 
(TRAIL-R3, CD263) and Dc-R2 (TRAIL-R4, CD264). Dc-R1 lacks the characteristic 
death domain and Dc-R2 contains a truncated non-functional death domain. These 
decoy-receptors are believed to negatively regulate TRAIL-induced apoptosis by 
competing for ligand binding (Sheridan et al., 1997). However, many cancer cells appear 
not to express these decoy receptors, making TRAIL-R1 and R2 to be potential targets 
for anti-cancer treatment. TRAIL knockout mice suffer form higher incidence of 
developing autoimmune diseases, suggesting that TRAIL also plays a role in the 
apoptotic depletion of autoreactive T lymphocytes. The CD95 and TRAIL-R1/TRAIL-R2 
apoptotic signaling pathways are initiated upon binding to trimerized CD95L or TRAIL. 
This leads to trimerization of the receptor and clustering of the DD of the activated 
receptor in the cytoplasm. Several proteins associate with the DD of activated CD95 or 
TRAIL receptors and form a Death Inducing Signaling Complex (DISC) (Fig. 1.5). The 
adaptor molecule FADD (Fas-Associated Death Domain), which also contains a DD, is 
recruited and interacts with the DD of the activated receptor (Kischkel et al., 1995; 
Bolding et al., 1995; Chinnaiyan et al., 1995). FADD also contains a death effector 
domain (DED). Upon recruitment of FADD to the receptor, its DED interacts with the N-
terminal tandem DED of the initiator caspase, procaspase-8 (Fernandes-Alnemri et al., 
1996; Vincenz and Dixit, 1997) or procaspase-10 (Kischkel et al., 2001; Wang et al., 
2001; Sprick et al., 2002). However, whether caspase-10 can trigger cell death in the 
absence of caspase-8 in response to CD95 or TRAILR1/R2 stimulation is controversial 
(Walczak et al., 2002). Two types of cell death were established. Cells that have the 
ability to form high levels of CD95 DISC can effectively activate caspase-8 and directly 
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activate downstream effector caspases. These cells are called type I cells. Cells that 
have low levels of CD95 DISC formation must amplify the signal for cell death via the 
mitochondrial (Intrinsic) apoptotic pathway. These cells are called type II cells. 
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Figure 1.5: CD95 signaling pathways used in type I and type II cells.  
CD95 signaling used in type I cells is shown on the left side whereas signaling used in 
type II cells is shown on the right side. Type I cells have the ability to form high levels of 
CD95 DISC formation and can directly activate downstream effector caspase-3. Type II 
cells have low levels of CD95 DISC formation. Therefore, the signal must be amplified 
via the mitochondrial apoptotic pathway mediated by the pro-apoptotic BH3 only family 
member Bid. 
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1.6.3 The mitochondrial (intrinsic) cell death 
pathway 
The intrinsic cell death pathway can be induced by DNA damage, cytotoxic agents, 
hypoxia and deprivation of growth factors (Norbury and Zhivotovsky, 2004). An 
important trigger for the intrinsic cell death pathway is the mitochondrial outer membrane 
permeabilization (MOMP) which is largely regulated by members of the Bcl-2 (B-cell 
lymphoma-2) family (Chao and Korsmeyer, 1998). Bcl-2 family members are composed 
of pro- and anti-apoptotic proteins. Anti-apoptotic Bcl-2 family members such as Bcl-XL, 
Mcl-1 and Bcl-2 contain four conserved domains which are called Bcl-2 homology (BH) 
domains (BH1-BH4). Pro-apoptotic Bcl-2 family members can be further divided into a 
group of proteins containing the BH1-BH3 domains, such as Bax and Bak and a BH3-
only group such as Bim, Bad, Puma and Bid. The intrinsic cell death pathway is tightly 
controlled by these pro-and anti-apoptotic proteins of the Bcl-2 family. Following an 
apoptotic stimulus, Bax undergoes homodimerization and associates with the 
mitochondrial membrane. This results in changes of the mitochondrial permeabilization 
and the breakdown of the mitochondrial membrane potential (Petit et al., 1995; Zamzami 
et al., 1995). Bcl-2 or Bcl-XL, are shown to associate with the mitochondrial membrane 
and maintain the mitochondrial membrane potential by antagonizing the pro-apoptotic 
Bcl-2 family members Bax and Bak (Zha et al., 1997). Depolarization of the 
mitochondrial potential results in the release of pro-apoptotic proteins from the 
mitochondria such as Smac/Diablo (second mitochondria-derived activator of 
caspase/direct IAP binding protein with low PI) and cytochrome c in the cytoplasm. 
Smac/Diablo then inhibits the anti-apoptotic function of the IAPs. Released cytochrome c 
associates with Apaf-1 (apoptosis protease-activating factor 1) in an ATP-dependent 
way. Apaf-1 recruits and interacts via its CARD domain with the CARD domain of 
procaspase-9 (Hoffmann 1997). This protein complex is called the apoptosome and 
leads to the activation of caspase-9 which in turn activates effector caspases such as 
caspase-3, -6 and -7 (Acehan et al., 2002; Zou et al., 1999). The activation of these 
effector caspases lead to the activation of other caspases and the cleavage of 
substrates and ultimately to apoptosis. The death receptor pathway and the 
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mitochondrial apoptotic pathway are linked by the pro-apoptotic BH3 only family 
member, Bid. Upon stimulation, Bid is cleaved by caspase-8 to a truncated form (tBID) 
which translocates to the mitochondria where it acts together with the pro-apoptotic Bcl-
2 family members Bax and Bak to induce the intrinsic cell death pathway (Scaffidi et al., 
1998).  
1.6.4 c-FLIP, a regulator of death receptor-induced 
apoptosis  
To avoid uncontrolled cell death or tissue damage, apoptosis is tightly controlled on 
several levels. Receptor-mediated apoptosis can be regulated at the DISC by the 
presense of the cellular FLICE-like inhibitory protein (c-FLIP, FLAME-1, I-FLICE, 
Casper, CASH, MRIT, CLARP and usurpin), originally found in the family of 
herpesviruses. Several splice variants of c-FLIP have been reported to excist as RNA, 
but so far only three c-FLIP proteins have been found to be expressed. These include   
c-FLIPS, and c-FLIPR and c-FLIPL (Irmler et al., 1997; Scaffidi et al., 1999; Golks et al., 
2005) (Fig. 1.6). All FLIPs are characterized by two DEDs and can function as a 
dominant-negative inhibitor to block the recruitment of procaspase-8 to the DISC and 
thereby block cleavage and activation of caspase-8 (Krueger et al., 2001). c-FLIPS is 
similar in structure to viral FLIP (v-FLIP) of the herpesviruses, except that the two DEDs 
of c-FLIPS are followed by a short carboxy-terminal extension of around 20 amino acids 
that seems to be crucial for its ubiquitylation and therefore its proteasomal degradation. 
c-FLIPR also contains two DEDs but lacks the additional carboxy-terminal amino acids. 
c-FLIPL contains a longer C-terminal extension with a caspase-like region that is similar 
to procaspase-8 and procaspase-10. However, the C-terminal part of c-FLIPL lacks 
caspase enzymatic activity, due to the substitution of several amino acids, such as the 
cysteine residue, which is required for catalytic activity (Han et al., 1997; Hu et al., 1997; 
Inohara et al., 1997 Goltsev et al., 1997).  
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Figure 1.6: Molecular structure of viral and cellular c-FLIPs. 
All FLIP molecules contain two death-effector domains (DEDs), similar to caspase-8. The 
carboxy (C)-terminal regions vary in length and sequence. Viral FLIP (v-FLIP) was 
initially detected in γ-herpesviruses. C-FLIPS and c-FLIPR are similar in structure to the v-
FLIP except that c-FLIPS contains an extension of around 20 amino acids that is thought 
to be crucial for its ubiquitylation (red color). C-FLIPL contains a C-terminal inactive 
caspase-like domain, which is similar to procaspase-8 and procaspase-10. The short 
splice variants c-FLIPS and c-FLIPR lack such a caspase-like domain. 
 
Besides competing with procaspase-8 for recruitment to the DISC, c-FLIPL can form 
heterodimers with procaspase-8, which leads to the generation of a 43 kDa FLIP 
fragment (p43). FLIP-p43 can recruit other signaling molecules, such as Receptor-
interacting protein (RIP), TNF Receptor-Associated Factor 1 and 2 (TRAF1 and TRAF2) 
and promote thereby the activation of NF-ĸB and extracellular signal-regulated kinase 
(ERK)-mediated gene expression (Chaudhary et al., 2000; Kataoka et al., 2000; Kataoka 
and Tschopp, 2004). Therefore, CD95 also signals proliferation and differentiation 
(Zuliani et al., 2006). As c-FLIPs are key controllers of CD95L and TRAIL-R1/2 -induced 
apoptosis, their expression is strongly controlled. At the transcriptional level c-FLIP has 
been reported to be regulated by the nuclear factor of activated T cells (NFAT). 
Furthermore, it has been reported that c-FLIP is regulated by the transcription factor NF-
ĸB (Micheau et al., 2001; Kreuz et al., 2001). It has also been reported that c-FLIP 
expression in normal cells and tumor cells is induced at the translational level by the 
PI3K/Akt pathway and can thereby induce resistance towards TRAIL and CD95 induced 
apoptosis (Panka et al., 2001; Suhara et al., 2001; Poulaki et al., 2002; Uriarte et al., 
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2005). In activated T cells, c-FLIP expression has been shown to be dependent on the 
ERK/MAPK pathway. The addition of a dominant active MKK1 (MEK-1) induced c-FLIP 
expression in this case (Yeh et al., 1998). 
1.6.5 Modulation of apoptosis by Tax 
The viral protein Tax does not only affect cell proliferation but also apoptosis. HTLV-1 
infected T cell lines were shown to be resistant towards CD95-induced apoptosis 
(Copeland et al., 1994). A similar resistance towards CD95-mediated apoptosis was 
observed in T cells derived from transgenic mice carrying the tax gene (Kishi et al., 
1997). Analyses of these mice suggested that protection of peripheral T cells from 
CD95-mediated apoptosis by Tax is one of the important underlying mechanisms 
required for the immortalization of T cells and the development of ATL.  
Besides resistance towards CD95 mediated apoptosis, HTLV-1 infected T cell lines have 
also been shown to be resistant towards TRAIL mediated apoptosis (Matsuda et al., 
2005). The basis of apoptotic resistance in HTLV-1 infected T cells is the altered 
expression of proteins involved in the mitochondrial apoptotic pathway such as Bax and 
Bcl-XL. It has been shown that Tax can downregulate the expression of the pro-apoptotic 
protein Bax (Brauweiler et al., 1997) and up-regulate the expression of the anti-apoptotic 
protein Bcl-XL by induction of NF-ĸB (Tsukahara et al., 1999; Mori et al., 2001).  
1.7.1 Regulation of transcription by NF-ĸB 
NF-ĸB represents a family of structurally related inducible transcription factors that 
regulate diverse biological processes, including cell growth and survival of both T cells 
and nonlymphoid cells (Karin and Lin, 2002; Li and Verma, 2002). NF-ĸB proteins form 
homo- or heterodimers. At least five NF-ĸB proteins have been identified in mammalian 
cells, including p50 (NF-ĸB1), p52 (NF-ĸB2), p65 (RelA), RelB and Rel A, which can 
transactivate target genes containing a NF-ĸB binding site (Siebenlist et al., 1994; 
Verma et al., 1995; Baldwin, 1996). The NF-ĸB proteins are normally sequestered in the 
cytoplasm by physical interaction with inhibitors of NF-ĸB (IĸBs) (Verma et al., 1995; 
Baldwin, 1996). The latent NF-ĸB complexes can be activated by diverse immune 
stimuli, such as antigens, cytokines and microbial components, which target two 
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alternative NF-ĸB signaling pathways, namely the canonical or noncanonical pathway 
(Pomerantz and Baltimore, 2002). The canonical pathway is induced by several stimuli 
which lead to the phosphorylation of IĸBα. Phosphorylated IĸBα is then subjected to 
ubiquitination and degradation by the 26S proteasome. The degradation of IĸBα 
releases the p50/RelA and p50/cRel NF-ĸB dimers which translocate to the nucleus and 
activate NF-ĸB-responsive gene expression (Didonato et al., 1996; Chen et al., 1996; 
Karin and Ben-Neriah, 2000). Phosphorylation of IĸBα is carried out by an IĸB kinase 
(IKK) complex comprised of two catalytic subunits, IKKα and IKKβ and a regulatory 
subunit, IKKγ (Zandi et al., 1997; Yamaoka et al., 1998).  IKKγ, which is also known as 
NF-ĸB essential modulator (NEMO), has no kinase activity but likely functions as a 
scaffold protein, which assembles the IKK complex (Li et al., 2001). The IKK complex is 
activated by upstream kinases such as NF-ĸB inducing kinase (NIK) and the mitogen-
activated protein kinase /ERK kinase kinase-1 (MEKK1) (Nakano et al., 1998; Mercurio 
et al., 1997) which activate the catalytic subunits, IKKα and IKKβ. The kinase HPK1 
(Hematopoietic progenitor kinase 1) can also activate the IKK-complex and 
phosphorylates IKKβ in vitro (Brenner et al., 2005). After T-cell stimulation, caspase-3 
can cleave HPK-1 and the C-terminal part of HPK-1 which can in turn inhibit NF-ĸB 
activity (Arnold et al., 2001; Brenner et al., 2005).  
The noncanonical NF-ĸB pathway does not require the IKK complex but activation is 
mediated by upstream kinases and the IKKα subunit (Senftleben et al., 2001). This 
pathway is required for the activaton of specific NF-ĸB dimers as p52/RelB (Derudder et 
al., 2003) and is only used in specific cell types, such as B cells. In T cells and in most 
other cell types the signals are mediated by the canonical NF-ĸB pathway.  
To achieve temporal activation, the NF-ĸB pathway has a negative feedback 
mechanism. NF-ĸB induces the expression and synthesis of the inhibitory protein IĸBα 
(Scott et al., 1993). IĸBα is able to enter the nucleus and can stop the induction of NF-ĸB 
dependent gene expression. 
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1.7.2 Activation of NF-ĸB by Tax 
In contrast to the control of the NF-ĸB pathway in normal T cells, NF-ĸB is constitutively 
activated in freshly isolated ATL cells and HTLV-1-transformed T cell lines (Ballard et al., 
1988; Ruben et al., 1988; Leung et al., 1988). This constitutive activation is mediated by 
the Tax protein which serves as an intracellular NF-ĸB inducer and bypasses negative 
feedback mechanisms. Tax has been reported to activate NF-ĸB through various 
mechanisms and it has been thought to physically interact with several NF-ĸB family 
members such as p50 and RelA (Beraud et al., 1994). Later, it was also reported that 
Tax-mediated NF-ĸB activation occurs at the level of NF-ĸB nuclear translocation 
(Kanno et al., 1994; Mckinsey et al., 1996). This was also shown with a Tax mutant, 
defective in nuclear localization, which could still activate NF-ĸB-dependent gene 
transcription (Nicot et al., 1998). Furthermore it was shown that Tax can induce the 
phosphorylation and degradation of I-ĸBα which further suggested that the NF-ĸB 
signaling pathway is involved in Tax-mediated NF-ĸB activation (Brockman et al., 1995; 
Kanno et al., 1994; Sun et al., 1994). Tax physically associated with the canonical IKK 
complex, in which IKK was constitutively phosphorylated and activated (Chu et al., 1998; 
Carter et al., 2001) (Fig. 1.7). The activation of the IKK complex was dependent on the 
physical interaction between Tax and the IKK regulatory subunit IKKγ. IKKγ serves as 
an adaptor for recruiting Tax to the IKK catalytic subunits IKKα and IKKβ (Geleziunas et 
al., 1998; Uhlik et al., 1998). Constitutive activity of the IKK complex was detected in 
both Tax-transfected cells as in HTLV-1-infected cells. The physical interaction of Tax 
with the canonical IKK complex is probably the major mechanism by which HTLV-1 
induces persistent activation of NF-ĸB. However, other mechanisms may be involved in 
the maintenance of constitutive NF-ĸB activation. 
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NF-ĸB is constitutively activated in HTLV-1 infected T cell lines by the interaction of 
Tax with the IKK regulatory subunit IKKγ. IKKγ serves as an adaptor for recruiting Tax 
to the IKK catalytic subunits IKKα and IKKβ, which are phosphorylated and activated. 
This leads to the phosphorylation and ubiquitination of IĸBα, which is degradated by 
the 26S proteasome. The degradation of the I-ĸBs releases p50/RelA NF-ĸB dimers, 
which translocate to the nucleus and lead to the activation of NF-ĸB-responsive gene 
expression. 
Figure 1.7: Activation of NF-кB signaling by Tax.  
The constitutive activation of the NF-ĸB pathway in both HTLV-1 infected T cell lines and 
freshly isolated ATL cells suggests a critical role for NF-ĸB in the development of ATL. 
NF-ĸB may contribute to the abnormal growth and survival of infected T cells during the 
early stages of ATL disease progression by the induction of genes involved in T-cell 
proliferation and apoptosis inhibition. In addition, the constitutive NF-ĸB activity also 
likely promotes the genetic changes that drive the progression of T cell transformation.  
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1.7.3 Activation of CREB by Tax 
Tax does not only have the capacity to activate NF-ĸB but can also activate other 
transcription factor such as the cAMP responsive element (CRE) binding factor (CREB) 
(Yoshida, 2001). In the normal regulation of CRE dependent transcription, is 
phosphorylated by protein kinase A upon stimulation of the cell, and phosphorylation 
allows its binding to a transcriptional co-activator, CBP (CREB binding protein). CBP 
associates with a specific 21-pb enhancer sequence and transcriptional initiation can 
occur. Tax interacts with CBP and forms a bridge between CREB and CBP without any 
specific phosphorylation of CREB (Brady et al., 1987; Jeang et al., 1988; Suzuki et al., 
1993; Franklin and Nyborg, 1995). In this way, Tax trans-activates the HTLV-1 genome 
by directing the Tax-CBP/p300 complex to a 21-bp enhancer sequence located in the 
HTLV-1 LTR but it can also activate several cellular genes using similar mechanisms. 
Besides trans-activation, Tax also has the ability to trans-repress the activity of CREB 
(Franklin and Nyborg, 1995; Azran et al., 2004). High affinity of the Tax-CBP/p300 
complex to transcription factors results in trans-activation, but weak affinity results in 
trans-repression.  
The activation of transcription factors by Tax leads to the modulation of expression of a 
wide range of cellular genes (Yoshida, 2001). Some of them are directly involved in the 
activation of T-cell proliferation, such as interleukin 2 (IL-2) (Good et al., 1996), the α-
subunit of its receptor (IL-2Rα) (Crenon et al., 1993), IL-15 (Azimi et al., 1998) and its 
receptor (IL-15R) (Mariner et al., 2001), granulocyte-macrophage colony stimulating 
factor (GM-CSF) (Himes et al., 1993) and others. The induction of IL-2Rα and IL-15R 
and their ligands by Tax lead to an autocrine activation loop (Maruyama et al., 1987). 
All together, the activation of a wide range of cellular genes leads to the deregulation of 
many important processes, including cell cycle regulation and apoptosis, resulting in  
transformation of HTLV-1 infected T cells.  
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1.8  Therapeutic approaches 
Despite advances in the knowledge of the molecular biology of HTLV-1 and ATL no 
effective treatment is available. The prognosis for ATL remains poor with a median 
survival of less than 1 year. Treatment of ATL has been of limited success due to the 
resistance of ATL cells towards apoptosis, the associated immunosuppression and the 
poor performance status of the patients (Siegel et al., 2001). ATL is generally treated 
with an aggressive multidrug approach of chemotherapeutic agents. So far, the 
combination of cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) has 
been the first line therapy. In some clinical studies CHOP has been combined with other 
agents as etoposide, vindesine, ranimustine and mitoxantrone (Taguchi et al., 1996). 
Also, clinical studies are performed with an aggressive multidrug approach with a 
combination of vincristine, cyclophosphamide, doxorubicin and prednisone (VCAP), 
doxorubicin, ranimustine, and prednisone (AMP), and vindesine etoposide, carboplatin, 
and prednisone (VECP). Although these combinations are generally associated with an 
increase in response rate and response duration, the overall survival remains poor with 
survival rates between 5.5 and 13 months (Yamada et al., 2001). Besides 
chemotherapy, several new approaches for the treatment of patients with ATL have 
been proposed. Combination of the antiretroviral drug zidovudine and interferon-α (IFN-
α) was reported to have significant activity in patients with ATL including those where 
chemotherapy had failed before. The constitutive activation of NF-ĸB in HTLV-1 infected 
T cells makes it an attractive target for therapy. A number of different approaches point 
to the therapeutic potential of NF-ĸB inhibition. The NF-ĸB inhibitor, Bay 11-7082, down-
regulates the expression of the anti-apoptotic protein Bcl-XL which is highly upregulated 
in HTLV-1 infected T cells. Inhibition of the proteasome by PS-341 (bortezomib) blocked 
the degradation of IĸBα and thereby the inhibition of NF-ĸB.  Both approaches lead to 
the induction of apoptosis in HTLV-1 infected T cells in vitro (Tan et al., 2002; Satou et 
al., 2004).   
An alternative approach is to target cell differentiation markers on the HTLV-1 infected T 
cells with monoclonal antibodies. The high expression of the IL-2α receptor (CD25) has 
made it an attractive target. Patients are treated with an anti-CD25 monoclonal antibody 
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(daclizumab) with or without labeled Yttrium90 (Waldmann et al., 1988; Waldmann et al., 
1995). A study of humanized anti-CD25 antibody therapy in combination with CHOP 
chemotherapy is currently ongoing. 
Currently there is no clear evidence to support the value of any particular treatment 
approach with respect to treatment response. Although some therapies were reported to 
be partly effective, no convincing therapeutic benefits have been established. Therefore 
new molecular targeting strategies and the development of new drugs are important. 
1.9.1 Plants, sources of new drugs   
Plant-derived substances have traditionally played an important role in the treatment of 
human diseases. About 80% of the world population living in third world countries, 
almost entirely rely on plant products for their health care. Also in the western world 
pharmaceuticals are frequently derived directly from plant products. Examples include 
aspirin (originally derived from the Rosacea Filipendula ulmaria) and the prescription 
drug morphine (derived from Papaveracea Papaver somniferum). Although plant 
extracts have been used for over 3,500 years in the treatment of several diseases, it 
was only since the late 1950s that it became clear that plant-derived compounds could 
also play an important role in the treatment of cancer therapy. These compounds exert 
their antiproliferative effect on various intracellular targets. Many if not all applications of 
these drugs finally result in an inhibition of cell proliferation depending on the 
concentration used in the individual experiments.  
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1.9.2 The plant genus Aglaia and its rocaglamide 
derivatives 
Many research institutions and industrial pharmaceutical laboratories apply random 
screening approaches of plants extracts for interesting compounds. Such strategies 
have been estimated to require the evaluation of approximately 20.000 candidate plant 
extracts to obtain one clinical useful drug. In one of these screenings it was found that 
the plant genus Aglaia of the family Meliaceae could be a potential source of interesting 
compounds (Fig.1.9). 
 
Figure 1.9: Aglaia odorata of the family Meliaceae, source of 
cyclopenta[b]benzofuran compounds (Rocaglamide). 
The genus Aglaia consists of approximately 130 species mostly found in countries in 
South-East Asia. Plant extracts from several Aglaia species are already used in 
traditional medicine for the treatment of inflammatory skin diseases and asthma. The 
active compounds isolated from these plant extracts are derivatives of 
cyclopenta[b]benzofuran, also called rocaglamide (King et al., 1982). Since rocaglamide 
was found to be the active compound, investigation has led to the isolation of many 
related compounds. To date, 60 naturally occurring rocaglamide derivatives have been 
isolated from over 30 Aglaia species.  
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The majority of these naturally occurring derivatives have strong insecticidal activity as 
analyzed in the larvae Spodoptera littoralis. Most of the rocaglamide derivatives tested 
had a LC50 value ranging between 1-2 ppm which is comparable with the LC50 of the 
insecticide azadirachtin (Brader et al., 1998). Besides their insecticidal activity, 
rocaglamide derivatives have also been tested for their possible antiproliferative activity 
in cancer cell lines. Up to now, over 40 rocaglamide derivatives have been tested in in 
vitro assays against several cancer cell lines, and most of these compounds showed 
significant cytostatic activity with IC values comparable to that of the well known anti-
cancer agent vinblastine (Lee et al., 1998; Kim et al., 2006). Rocaglamide derivatives 
differ usually from each other by the nature of their substituents at the positions, R1 (-
OH) vs. –OAC), R2 (different amino acyl substituents vs. – COOCH3 group) and/or R3 (- 
H vs. –OH or –OCH3) whereas the substitution pattern at the remaining carbons of the 
rocaglamide skeleton as well as the absolute configuration of the various congeners are 
remarkably stable (Nugroho et al., 1997) (Fig. 1.10). The activity of the several 
rocaglamide derivatives is dependent on the different substituents, as analyzed in 
previous studies (Bohnenstengel et al., 1999).  
 
 
 
 
 
Figure 1.10: Chemical structures of several Rocaglamide derivatives.  
The structure of the rocaglamide derivative used in this study, 1-oxo-11, 12-
methylendioxy-rocglaol, abbreviated as Roc-AR, is number 38.  
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Although the rocaglamide derivatives are known to exhibit cytostatic activity, their 
molecular target(s) have not been identified. Recent investigations have focused on the 
cellular mechanism of action of these compounds. It has been reported that some 
members of this class of compounds inhibit cell proliferation in human monocytic 
leukemia cell lines (Bohnenstengel et al., 1999). Later on, it was reported that 
rocaglamide derivatives can inhibit TNF- and PMA (phorbol 12-myristate 13-acetate)-
induced NF-ĸB activity (Baumann et al., 2002). More recently, our group has shown that 
rocaglamide derivatives inhibit NFAT activity in activated T cells (Proksch et al., 2005). It 
was demonstrated that rocaglamide derivatives selectively inhibit the NFAT-dependent 
gene expression of several cytokines after stimulation with anti-CD3/anti-CD28 or 
PMA/ionomycin in peripheral blood T cells. The tested rocaglamide derivatives inhibited 
NFAT at a concentration between 25-100 nM whereas NF-ĸB activity was not affected 
(Proksch et al., 2005). Recent new data in our group suggests that these compounds 
can induce apoptosis in leukemia cells but not in normal peripheral blood lymphocytes. 
Taken together, rocaglamide derivatives show antiproliferative activity observed in vitro 
in several human cancer cell lines and in vivo in an experimental mouse model. 
Therefore, they are promising chemotherapeutic agents. The mechanism of the 
rocaglamide-mediated antiproliferative effect is not completely understood. Natural 
compounds exert their antiproliferative effect on various intracellular targets. For 
example, vinblastine inhibits tubulin polymerization (Bayssass et al., 1980), actinomycin 
D inhibits DNA replication (Guy and Taylor, 1978) and cycloheximide inhibits protein 
biosynthesis via the ribosomal machinery (Korner, 1966). Other natural products 
interfere with signal transduction pathways by inhibiting protein kinases such as the 
inhibition of the kinase mTOR by Rapamycin (Tsang et al., 2007). Applications of these 
drugs results in inhibition of cell proliferation which depends on the concentration used. 
The specificity of the drug for a certain molecular target and the amount needed for 
treatment decide largely about its use as a therapeutic agent.  
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1.10 AIM OF THE STUDY 
Human T cell Leukemia Virus Type 1 (HTLV-1) is a retrovirus, associated with several 
diseases including Adult T-cell Leukemia/Lymphoma (ATL). Because of apoptosis 
resistance therapeutic treatment provides only very limited benefits for ATL.  
CD95/CD95L-mediated apoptosis is an important mechanism of T cell homeostasis. We 
have previously shown that HTLV-1 infected T cells are more resistant towards 
apoptosis induced by CD95L as compared to non infected T cells. In this study, we  
address the question, whether these cells are more resistant towards death receptor-
mediated apoptosis in general and compare to other death receptors, like TRAIL 
receptors. 
The basis of apoptotic resistance in HTLV-1 infected T cells was suggested to be due to 
the elevated expression of several anti-apoptotic proteins involved in modulation of the 
intrinsic cell death pathway. Recently our group found that apoptosis is also blocked 
within the extrinsic cell death pathway by high c-FLIP expression. C-FLIP is an anti-
apoptotic protein that blocks death receptor-mediated apoptosis at the DISC level. 
The aim of this study is to develop a new approach to overcome resistance of HTLV-1 
infected T cells towards death receptor-mediated apoptosis. The herbal compound, 
Rocaglamide, derived from a Traditional Chinese Medicinal plant (TCM) should be 
tested to sensitize HTLV-1 infected T cells towards cell death. 
Although our lab recently showed that Rocaglamide derivatives exhibit antiproliferative 
activity on different leukemia cell lines and in leukemia cells freshly isolated form 
patients, their molecular target(s) have not been identified. Therefore, it is intended to 
find the molecular mechanism of resensitization by Rocaglamide. The ultimate goal of 
this study is to develop a strategy for the treatment of ATL and other types of T-cell 
tumors. 
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2 MATERIALS & METHODS 
2.1 Materials 
2.1.1 Chemicals 
All chemicals, unless stated otherwise, are purchased from Merck (Darmstadt), Roth 
(Karlsruhe), Fluka (Neu-Ulm), Serva (Heidelberg) and Sigma (München).  
2.1.2 Instruments 
Instrument Manufacturer 
Agarose gel electrophoresis apparatus Gibco BRL 
Autoradiography-Film (Kodak X-OmatTMLS) Kodak 
Bacterial shaker Certomat HK Braun 
Biofuge A Heraeus 
Biofuge Fresco Heraeus 
Cell culture Hood SG600 Baker Company 
Cell culture incubator Forma Scientific 
Centrifuge 5402 Eppendorf 
Developing system for X-Ray films Curix 160 Agfa-Gevaert 
Electrophoresis power supply Consort 865 Renner 
FACS scan flow cytometer Becton Dickinson 
FACS calibur flow cytometer Becton Dickinson 
Fine scale PE 3600 Mettler 
Freezer -20°C Liebherr 
Freezer -80°C Forma Scientific 
GeneAmp 5700 PE Applied Biosciences 
Heat block Thermostat 5320 Eppendorf 
Hemacytometer Neubauer HBG 
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Instrument Manufacturer 
Light microscope ID 02 Zeiss 
Megafuge 1.OR Heraeus 
Microwave HMG730B Bosch 
Mini gel electrophoresis apparatus Bio-Rad 
Nucleofector Electroporator Amaxa 
pH meter WTW WTW 
Phase contrast microscope Leitz 
quartz cuvettes Suprasil Hellma 
Scale AE 240 Mettler 
Semi Dry Blot Apparatus 20 x 25 cm CTI/Biorad 
Sorvall RC 3B PLUS, 5C PLUS Beckmann 
Spectrophotometer 6505 UV/Vis Jenway 
Spectrophotometer U-1100 Hitachi 
Thermocycler Perkin Elmer 
UV transilluminator Konrad Benda 
Vertical Gel Electrophoresis BRL 
Video Graphic Printer UP-860 CE Sony 
Water bath Köttermann 
x-ray developer Curix 160 Agfa-Gevaert 
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2.1.3  Solutions and buffers 
Buffer concentration Reagents 
PBS: 137 mM NaCl 
 8.1 mM Na2HPO4 
 2.7 mM KCl 
 1.5 mM KH2PO4 (pH = 7,4) 
FACS buffer (in PBS) 5% (w/v) FCS 
 0.1% (w/v) NaN3
Luciferase buffer 470 µM Luciferin (Photinus pyralis) 
 1.07 mM (MgCO3)4Mg(OH)2.5H2O 
 20 mM Tricin 
 2.67 mM MgSO4
 100 µM EDTA 
 33.3 mM DTT 
 270 µM  EDTA 
 33.3 mM  DTT 
 270 µM Acetyl-CoA 
 530 µM ATP 
Nicoletti lysis buffer 0.1% (w/v) Sodium citrate (pH 7.4) 
 0.1% (w/v) Triton X-100 
 50 µg/ml Propidium iodide 
TBE (10x) 0.45 M Tris base 
 0.45 M  Boric Acid 
 10 mM EDTA (pH = 8.3) 
TE 10 mM Tris base 
 1 mM EDTA (pH = 7.5) 
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Buffer (SDS-PAGE) concentration Reagents 
RIPA Lysis buffer 150 mM NaCl 
 1 mM DTT 
 1% (w/v)  Triton X-100 
 1 tablet / 50 ml Protease inhibitor Cocktail (Roche) 
 50 mM  Tris-HCL, pH= 8.0 
 0.5% Na-deoxycholate 
 2 mM EDTA (ethylene-diamine-tetra-acetate) 
 0.1% SDS 
 200 µM Na3VO4
 25 mM NaF 
Laemmli Stacking gel buffer (5%) 24 mM  Tris base (pH = 6.8) 
 5% (w/v) Acrylamide/Bisacrylamide 37.5:1 
 0.1% (w/v) SDS 
 0.1% (w/v) Ammoniumpersulfat (APS) 
 0.1% (w/v) Tetramethylethylendiamine (TEMED) 
Laemmli Resolving gel 37.5 mM Tris base (pH = 8.8) 
 7.5-15% (w/v) Acrylamid/Bisacrylamid 37.5:1 
 0.1% (w/v) SDS 
 0.03% (w/v) APS 
 0.1% (w/v) TEMED 
Transfer buffer (Western Blot) 25 mM  Tris base 
 0.19 M  Glycine 
 20% (v/v) Methanol 
 0,037% (w/v) SDS 
Blocking buffer 5% (w/v) non-fat dry milk in TBST 
SDS sample buffer (5 x) 50% (v/v) Glycerol 
 10% (w/v) SDS 
 50 mM  Tris base (pH = 6.8) 
 25% (v/v) β-Mercaptoethanol 
 0.25 mg/ml Bromphenol blue 
Running buffer (SDS-PAGE) 0.19 M  Glycin 
 0.1% (w/v) SDS 
 25 mM  Tris base (pH = 6.8) 
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Buffer (nuclear extract) concentration Reagents 
Buffer A 10 mM HEPES (pH 8.0) 
 0.5 M Sucrose 
 50 mM NaCl 
 0.25 mM  EGTA 
 1 mM EDTA 
 0.5 mM  Spermidine 
 0.5 % Triton x-100 
 1 µg/ml Trypsin 
 0.5 mM PMSF 
 0.5 µg/ml Leupeptin 
 0.7 µg/ml Pepstatin 
 1 µg/ml Aprotinin 
 40 µg/ml Bestatin 
Buffer B 10 mM HEPES (pH 8.0) 
 25% Glycerol 
 500 mM NaCl 
 0.1 mM  EGTA 
 1 mM EDTA 
 0.5 mM  Spermidine 
 0.25 mM DTT 
 0.5 mM PMSF 
 0.5 µg/ml Leupeptin 
 0.7 µg/ml Pepstatin 
 1 µg/ml Aprotinin 
 40 µg/ml Bestatin 
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2.1.4 Eukaryotic Cell lines and bacterial strains 
Cell lines Description 
Jurkat Human acute lymphoblastoid T cell line 
CEM Human acute lymphoblastoid T cell line 
SP HTLV-1 infected leukemia T cell line 
MT-2 HTLV-1 infected lymphoblastoid T cell line 
ATL-3 HTLV-1 infected leukemia T cell line 
CHAMP HTLV-1 infected leukemia T cell line 
 
 
Bacterial strain Source 
DH5α Bethesda Research Laboratories 
2.1.5  Culture media bacteria 
Bacterial culture Medium Composition  
90 g NaCl 
90 g Casein hydrolysate (Roth) 
45 g Yeast extract (Gerbu) 
LB (Luria-Bertani) medium 
(10x) 
(Adjust pH to 7.5 with NaOH) 
  
For the preparation of 10 LB-plates, 4.5 g of bacto-agar were added to 300 ml of LB 
medium, autoclaved and cooled down to 50°C in a water bath. At this temperature 
ampicillin (50 μg/ml) was added. After cooling down, petri dishes were filled with the 
solution. The plates were stored at 4°C until usage. 
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2.1.6  Culture media eukaryotic cell lines 
Cell culture medium 1640 is obtained from GibcoBRL in powder form and solved in H2O 
as described. The medium was sterilized and stored at 4 °C. Before usage FCS, 
Gentamycin, L-glutamine were added. The final composition of the medium is shown 
below. Prior addition to the medium Fetal Calf Serum (FCS) was heat inactivated for 30 
min at 56 °C. For primary human T cells IL-2 (25 U/ml) was added to the medium. 
 
Human cell culture medium Composition  
900 ml  RPMI 1640 (GibcoBRL) 
10% FCS (GibcoBRL) 
10 mg/ml Gentamycin (GibcoBRL) RPMI  medium (complete) 
2 mM L-glutamine (Invitrogen Life 
Technologie) 
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2.1.7  Antibodies for western blot analysis 
Name antigen Origin 
C15 (IgG2b) caspase-8 Scaffidi et al, 1997 
NF6 (IgG1) c-FLIP Scaffidi et al, 1999 
anti-FADD (IgG1) FADD Transduction Laboratories 
anti-Erk1 (MK12) Erk BD Biosciences 
anti-Mek1/2 (47G9) Mek1/2 Cell Signaling Technology 
anti-phospho-Mek1/2 (41G9) phospho-Mek1/2 Cell Signaling Technology 
anti-Caspase-3 (9662) Caspase-3 Cell Signaling Technology 
anti-phospho-ERK (E-4) Phospho-Erk Cell Signaling Technology 
anti-phospho-mTOR (2971) Phospho-mTOR Cell Signaling Technology 
anti-mTOR (2972) mTOR Cell Signaling Technology 
anti-phospho-Mnk1 (2111) Phosphor-Mnk1 Cell Signaling Technology 
anti-phospho-eIF4E (9741) Phospho-eIF4E Cell Signaling Technology 
anti-eIF4E (9742) eIF4E Cell Signaling Technology 
anti-eIF4G (2441) eIF4G Cell Signaling Technology 
anti-p38 (5F11) p38 Cell Signaling Technology 
anti-phospho p38 (V121A) Phospho-p38 Promega 
anti-Tubulin (clone B-5-1-2) tubulin Sigma 
anti-Tax hybridomas (clone 168B17-46-
34 and 168B17-46-50) 
Tax 
NIH AIDS Research & 
Reference Reagent Program  
anti-Mnk1 (C-20) (sc-6965) Mnk1 Santa Cruz Biotechnology 
anti-Cyclin D1 (M-20) Cyclin D1 Santa Cruz Biotechnology 
anti-Cyclin D2 (C-17) Cyclin D2 Santa Cruz Biotechnology 
anti-Cyclin B (554178)  Cyclin A BD Biosciences 
anti-Cyclin E (E-4) Cyclin E Santa Cruz Biotechnology 
anti-IgG, HRP 
(Goat, polyclonal) 
Mouse IgG Jackson 
anti-IgG1, HRP Mouse IgG1 Southern Biotechnology 
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(Goat, polyclonal) 
anti-IgG2a, HRP 
(Goat, polyclonal) 
Mouse IgG2a Southern Biotechnology 
anti-IgG2b, HRP 
(Goat, polyclonal) 
Mouse IgG2b Southern Biotechnology 
anti-Rabbit, HRP 
(Goat, polyclonal) 
Rabbit IgG Santa Cruz Biotechnology 
 
2.1.8 Antibodies for FACS analysis 
Name (serum/isotyp) Antigen Origin 
anti-CD69-FITC CD69 BD Pharmingen 
anti-APO-1 (IgG3) CD95 Trauth et al., 1989 
NOK-1 CD95L BD Pharmingen 
HS101 (IgG1) TRAIL-R1 Alexis 
HS201 (IgG1) TRAIL-R2 Alexis 
HS301 (IgG1) TRAIL-R3 Alexis 
HS402 (IgG1) TRAIL-R4 Alexis 
anti-IgG1, PE 
(goat, polyclonal) 
mouse IgG1 BD Pharmingen 
anti-IgG1, FITC 
(goat, polyclonal) 
mouse IgG1 Jackson 
anti-IgG1 antibody was conjugated with FITC (Fluorescein-Isothiocyanat λEx/Em/max 
488/514 nm), or with PE (R-Phycoerythrin λEx/Em/max 488/575 nm). 
 
50
Materials & Methods 
2.1.9  Reagents 
Reagents Reference 
anti-APO-1 Trauth et al., 1989 
Leucine zipper (LZ)–CD95L Walczak et al., 1999 
Super-TRAIL Alexis 
Cycloheximide Sigma 
Rocaglamide derivative Roc-AR Proksch et al., 2005 
Rapamycin Sigma 
Actinomycin D Sigma 
Phorbol-12-myristate-13-acetate 
(PMA) 
Merck 
Ionomycin  Merck 
2.1.10 Plasmids 
Name Plasmid 
pcDNA3 Eukaryotic expression vector (Invitrogen) 
4 x NF-ĸB Contains four copies of the NF-ĸB consensus sequence (GGA AAT 
TCC CC) (Li-Weber et al., 1998) 
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2.1.11 Primers 
 Target gene Sequence 
c-FlipL forward 5′-AAT TCA AGG CTC AGA AGC GA-3′ 
c-FlipL reverse 5′-GGC AGA AAC TCT GCT GTT CC-3′ 
c-FlipS forward 5′ GGC CGA GGC AAG ATA AGC AAG G-3′ 
c-FlipS reverse 5′-GCG CGG TAC CTC ACA TGG AAC AAT TTC CAA G-3′ 
β-actin forward 5′-GCC CCC CTG AAC CCC AAG GCC AAC-3′ 
β-actin reverse 5′-CCG CTC GGC CGT GGT GGT GAA GCT-3′ 
CD95L forward 5′-ATA GGA TCC ATG TTT CTG CTC TTC CAC CTA CAG AAG GA -3′ 
CD95L reverse 5′-ATA GAA TTC TGA CCA AGA GAG GCT CAG ATA CGT TGA C-3′ 
Tax forward 5′-ATG GCC CAT TTC CCA GG-3′ 
Tax reverse 5′-TCA GAC TTC TGT TTC TCG G-3′ 
 
The used DNA oligonucleotides are synthesized and obtained from MWG Biotech.  
2.1.12 Kits 
Enzyme/kit  Origin 
Reverse Transcriptase Appplied Biosystems 
T4 DNA Ligase MBI Fermentas 
Taq DNA Polymerase MBI Fermentas 
High Fidelity PCR Kit Roche 
RNA Microprep Kit  Stratagene 
NucleoSpin RNA II kit Macherey-Nagel 
Gel Extraction Kit Qiagen 
Plasmid Maxi Kit  Qiagen 
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2.2 Molecular biological methods 
2.2.1 Preparation of competent bacteria 
For preparation of competent bacteria, 10 ml of an O/N culture of DH-5α E.coli were 
inoculated into 300 ml LB-media and further cultured at 37°C in a shaker until the OD600 
= 0.6. The bacterial culture was cooled down for 10 min and then pelleted by 
centrifugation at 4000 rpm at 4°C for 5 min. The supernatant was discarded and the 
pellet was resuspended in 40 ml ice-cold 100 mM CaCl2 buffer and incubated on ice for 
10 min. This step was repeated two times. The pellet was resuspended in 8 ml ice-cold 
100 mM CaCl2 buffer, incubated on ice for 10 min and aliquoted. Aliquots of 100 µl cell 
suspension were stored at -80°C until usage.  
2.2.2 Transformation of plasmid DNA in competent bacteria 
Competent bacteria (100 µl) were thawn on ice and plasmid solution was gently mixed 
with the bacterial solution and incubated on ice for 30 min. After 30 min a heat shock 
was performed at 42 °C for 1 min. The reaction mix was transferred to a LB-agarose 
plate containing ampicillin (50 µg/ml). The plate was incubated O/N at 37 °C. 
2.2.3 Plasmid DNA purification 
The purification of plasmid DNA was performed with the Plasmid Maxi Kit (Qiagen). 
Bacteria containing the transformed plasmid were cultured in 300 ml LB medium 
containing 50 µg/ml Ampicillin, O/N at 37 ºC in an incubator (300 rpm). The next day, the 
bacteria were harvested by centrifugation at 6000 x g for 15 min at 4 ºC. After discarding 
the supernatant, the bacterial pellet was resuspended in 10 ml of the supplied buffer P1. 
To lyse the cells, 10 ml of buffer P2 were added to the samples, mixed by inverting the 
tube 4-6 times, and incubated at RT for 5 min. To stop the lysis, 10 ml of chilled buffer 
P3 was added, mixed well, incubated on ice for 20 min, and then centrifuged at 13.000 x 
g. The QIAGEN-tip 500 columns were equilibrated by applying 10 ml of buffer YBT, and 
the column was allowed to drain by gravity. The supernatant containing the plasmid was 
filtered through a filter paper into the column and allowed to enter the column by gravity. 
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The column was washed 2 times with 30 ml of buffer QC. To elute the plasmid DNA, 15 
ml of buffer QF was applied to the column and the eluate was collected into a fresh tube. 
The DNA was precipitated by adding 0.7 volumes (10.5 ml) of isopropanol, followed by 
centrifugation at 4 ºC at 13000 x g for 30 min. The DNA pellet was washed with 5 ml of 
70% ethanol and centrifuged again at 4 ºC for 15 min. After pouring off the ethanol, the 
pellet was dried at RT and then resuspended in the required amount of sterile water.  
2.2.4  Restriction enzyme digestion and ligation of DNA fragments 
The plasmid DNA and DNA fragments were prepared by cutting it with suitable 
restriction enzymes for 1hr at 37 ºC in a following typical reaction:  
 
Cutting of DNA fragments obtained by PCR 
5 µl DNA fragment 
1 µl restriction enzyme 
5 µl  buffer 10x 
Add to 50 µl with H2O 
 
 
Cutting of plasmid DNA 
1 µg plasmid 
1 µl restriction enzyme 
5 µl  buffer 10x 
Add to 50 µl with H2O 
 
The fragments were separated on an agarose gel and purified out of the gel. For 
ligation, 1:3 molar ratio of vector:insert DNA fragments together with 1 µl of T4 DNA 
ligase were incubated in 1x ligation buffer in a total volume of 20 µl at 16 ºC O/N.  
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2.2.5 Measurement of DNA concentration  
The concentration of DNA was determined by measuring the absorbance at 260 nm 
using a spectrophotometer. For measuring the absorbance, the spectrophotometer was 
first calibrated with 100 µl of H2O. Then 5 µl of DNA sample was diluted with 95 µl H2O, 
transferred to a quartz cuvette, and the absorbance was recorded at 260 and 280 nm. 
The concentration of DNA was calculated by using the following formula: 
Absorbance at 260 nm (A260) x dilution factor x 50 µg/ml = x µg/ml 
2.2.6 Total RNA extraction 
Total RNA was extracted from cells (5 x 106) using the NucleoSpin RNA II kit 
(Macherey-Nagel). Briefly, cells are centrifuged at 1500 rpm for 5 min and a mixture of 
350 µl Buffer RA1 and 3.5µl β-ME was added to the pellet. The sample are passed 
through a syringe fitted with a 20-gauge needle four to six times and then loaded on a 
column and centrifuged at 13000 rpm for 1 min. The flow through was mixed with 350 µl 
70% ethanol and the sample is loaded in a NucleoSpin column and centrifuged for 
13000 rpm for 30 sec. The DNase I reaction buffer is prepared by adding 10 µl DNase I 
to 90 µl DNase I reaction buffer, loaded on a column and incubated for 15 min at RT. 
After adding 200 µl buffer RA2, the sample is centrifuged for 13000 rpm for 30 sec and 
the NucleoSpin column is placed into a new 2 ml collection tube. Then the samples are 
washed with 600 µl buffer RA3 and centrifuged at 13000 rpm for 30 sec. This step is 
repeated and the NucleoSpin column is placed into a 1.5 ml microcentrifuge tube. The 
RNA is eluted by adding 60 µl Nuclease-free water and centrifuged at 13000 for 1 min. 
The mRNA samples were stored at -80°C. 
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2.2.7 Reverse-Transcription reaction for cDNA generation (RT) 
Total RNA was isolated from cell lines with the NucleoSpin RNA II kit. Buffers and 
reagents were obtained from the RNA PCR Core Kit (Applied Biosystems). For the 
Reverse Transcriptase reaction the following components were prepared: 
volume Reagents 
2 µg RNA 
8 µl 25 mM MgCl2
4 µl 10 x PCR buffer II 
4 µl dNTP-Mix (each 10 mM dATP, dCTP, dGTP, dTTP) 
2 µl 100 mM Oligo-(dT)16
2 µl RNase inhibitor 
2 µl MuLV Reverse Transcriptase 
Filled to 40 µl RNase-free H2O 
 
The mixture was incubated in a Thermocycler (Biorad) at the following temperatures: 
 
15 min 25ºC 
45 min 42ºC 
5 min 95ºC 
 
The cDNA is stored at -20ºC. For PCR reactions, 5 µl is used in a total volume of 50 µl.   
2.2.8 Polymerase Chain Reaction (PCR) 
First, the template DNA must be denatured, which means that the strands of its helix 
must be unwound and separated-by heating to 95°C. The second step is hybridization or 
annealing, in which the primers bind to their complementary bases on the now single-
stranded DNA. The third is DNA synthesis by a polymerase, called the elongation step. 
The PCR products were electrophoretically separated on a 1% agarose gel containing 
ethidium bromide.  
 
 
56
Materials & Methods 
The following components are used in the PCR reaction mixture: 
 
volume Reagents 
5 µl 10 x PCR buffer 
1 µl dNTP-Mix (each 10 mM dATP, dCTP, dGTP, dTTP) 
1 µl Primer forward (100 pmol) 
1 µl Primer reverse (100 pmol) 
20 ng DNA template 
1µl Taq DNA-polymerase 
 Add to 50 µl with H2O 
 
The PCR reaction contained the following steps. 
  time Temperature 
 start 5 min 95 ºC 
Denaturation 1 min 95 ºC 
Annealing 1 min 58 ºC 25-30 cyclus 
Elongation 2 min 72 ºC 
 Termination 10 min 72 ºC 
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2.2.9 Purification of PCR products  
Purification of PCR products prior to restriction enzyme digestion was done with the 
PCR purification kit (Qiagen). All centrifugation steps were performed at 10.000 g in a 
conventional table top micro centrifuge. 5 volumes of buffer PB, which is provided by the 
kit, was mixed with 1 volume of the PCR sample. A QIAquick spin column was placed in 
a 2 ml collection tube. The mixture was applied to the QIAquick column and centrifuged 
for 1 min. The flow through was discarded. 0.75 ml wash buffer PE from the kit was 
added to the QIAquick column and centrifuged for an additional 1 min to completely 
remove the residual buffer. The QIAquick column was transferred in a clean 1.5 ml micro 
centrifuge tube and the DNA was eluted. 50 µl H2O was placed directly on the filter and 
left on the column for 2 min. Then the column was centrifuged for 1 min. DNA 
concentration was analyzed, using spectrophotometry.   
2.2.10 Quantitative real-time PCR 
Cells were treated as described and total RNA was extracted, quantified and reverse 
transcribed. The cDNA obtained from reverse transcription of 10 ng of total RNA was 
used for each reaction. First the PCR master mix was prepared as follows: 
Volume in µl Reagents 
1.25 PCR buffer (2x) 
2.50 MgCl2 (10 mM) 
1.00 dNTP-Mix (200 µM) 
0.0625 Hot Gold Star enzyme (0.05 U) 
0.125 Uracil-N-glycosylase(0.02 U) 
1.30 H2O 
 
 
The cDNA was pipetted into a 96 well plate and the following components were added to 
each reaction. Each reaction was done in triplicates in a total volume of 25 µl.  
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Reagents c-FLIPs β-actin 
Forward primer 5.3 5.3 
Reverse primer 5.3 15.8 
Probe Taq 3.5 3.5 
cDNA template 4.4 4.4 
PCR mix 43.8 43.8 
H2O 25.4 14.9 
 
Quantitative RT PCR was performed using a GeneAmp 5700 RT PCR detection system 
for 40-45 cycles. The median Ct values were taken, and the standard deviations were 
calculated from the triplicates. Gene expression levels were determined by relative 
quantification using β-actin as internal control gene for normalization. 
2.2.11 Agarose gel electrophoresis 
Double stranded DNA fragments can be separated according to their size on agarose 
gels. Agarose was added to 0.5 x TAE-buffer to obtain a final concentration between 
1.0% (w/v)- 2.0% (w/v). The agarose supension was boiled in a microwave until it is 
completely solubilized. The agarose is cooled down to ~ 50ºC and then ethidium 
bromide was added to the final concentration of 0.5 µg/ml. DNA samples were mixed 
with 1/6 volume of 6x loading buffer and loaded on the agarose gel. Besides the 
samples, also a DNA-size marker of 10 kb was loaded. The gel was run for 0.5-1 h with 
100 V. DNA fragments were visualized under UV illuminiation (366 nm) in a BioRad Gel 
Documentation system (BioRad life sciences). 
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2.2.12  Purification of DNA fragments from agarose gels  
To obtain the desired DNA fragments, the gel was cut by using a scalpel and transferred 
to an Eppendorf tube. DNA was purified according to the QIAquick Gel Extraction kit 
(Qiagen). Briefly, the DNA fragment was excised from the agarose gel with a clean, 
sharp scalpel. The gel slice was transferred in a tube and 3 volumes of buffer QG were 
added to 1 volume of gel. The mixture was incubated at 50 ºC with shaking for 10 min to 
dissolve the gel. When the gel was dissolved completely, one gel volume of isopropanol 
was added to the mixture. The mixture was applied to a QIAquick column and 
centrifuged for 1 min. The flow-through was discarded and the QIAquick column was 
placed back in the same collection tube. The DNA was washed with 0.75 ml of buffer PE 
and centrifuged again for 1 min. The flow-through was discarded and the QIAquick 
column was centrifuged for an additional min and the QIAquick column was placed into 
a 1.5 ml Eppendorf tube. DNA was eluted by adding 50 µl buffer EB to the center of the 
membrane and centrifuged for 1 min. DNA was stored at -20 ºC before further use.   
2.2.13 Preparation of protein lysates for SDS-PAGE 
1 x 107 cells were washed twice with ice-cold PBS and then resuspended in 200 µl of 
RIPA buffer and incubated for 20 min on ice. The cells were centrifuged for 20 min at 
13000 rpm at 4ºC and the supernatant was transferred to a new tube. 5 x sample 
loading buffer was added to the samples and incubated at  95ºC for 10 min and stored 
at -20ºC until used for SDS-PAGE.  
2.2.14 Preparation of nuclear extracts 
The entire preparation procedure was carried out at 4 ºC and all reagents must be kept 
on ice. 1 x 108 cells were resuspended in buffer A (10x pellet volume) and after 
vortexing the nuclei were collected by centrifugation at 3500 rpm for 5 min. The nuclei 
were resuspended in 500 µl buffer A and centrifuged at 4000 rpm for 5 min. Then the 
nuclei were lyzed in 500 µl buffer B by vortexing several times during incubation for 1 hr 
at 4 ºC. The extracts containing the nuclear proteins were collected by centrifugation at 
13000 rpm for 10 min. The nuclear extracts were stored at -80 ºC.  
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2.2.15 SDS PAGE 
The glassplates, comb, and separators were washed and dried. The plates, separators, 
and gel apparatus were carefully assembled to prevent leaks. The buffer for the 
resolving gel was made in a 50 ml disposable tube by mixing the above ingredients. The 
TEMED and 10% APS were added at last. The solution was mixed well by swirling the 
solution. The solution was pored using a P1000 from the side of the glassplate and 
covered with a 5 mm 80% ethanol layer on top of the gel. After polymerization of the gel 
for about 20 min the gel apparatus was hold upside-down to drain the 80% ethanol. The 
stacking gel was made in a 50 ml disposable tube by mixing above ingredients and 
again pored with a P1000 on top of the separating gel. Then the comb was inserted 
carefully and the stacking gel was polymerized for about 20 min. The comb was 
removed, the gel was washed with distilled H2O and the gel is transferred into a running 
container. Both chambers were filled with running buffer, making sure that all the wells 
were full of running buffer and that air bubbles were displaced from the wells. The 
samples were prepared as described before and loaded into the wells. The use of 
special narrow pipette tips can maximize the volume that can be loaded by starting at 
bottom of the well and slowly raising tip during loading process. Unused wells were 
loaded with the same SDS-containing buffer used to prepare the samples.The gel was 
run at 40 mA until the dye front reached the bottom of the gel. 
2.2.16 Western blot 
After running the gel with SDS-PAGE the proteins were transferred to a nitrocellulose 
membrane (Amersham) using a Trans-Blot Semi-dry Transfer chamber (BioRad).  
Therefore the gel was rinsed by submerging it briefly in the chilled transfer buffer and 
transferred to the transfer chamber on top of three pre-wet filter papers and a 
nitrocellulose membrane presoaked in transfer buffer. A 15 ml disposable tube was used 
to gently remove any bubbles that may be trapped underneath the gel. Three pre-wet 
filter papers were placed on top of the gel. Transfer took place at 60 Volts for 120 min. 
After transfer, the gel was removed from the transfer chamber and was transferred  to a 
small container containing blocking milk solution and was incubated for 1 hr at RT on a 
shaker to decrease unspecific binding of the primary antibody. Immediately after 
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blocking, the diluted primary antibody solution was added and incubated in a closed 
container at 4ºC O/N. Then the membrane was washed three times for 5 min with wash 
buffer. After washing the membrane, the secondary antibody was incubated for 1 hr at 
RT and washed again three times with wash buffer for 5 min and placed in a film 
cassette. For developing the Western-Blot, the detection kit ECL reagent (PerkinElmer 
Life Sciences) was used according to the protocol. Briefly, the detection solution A and B 
were mixed in a ratio of 1:1, and the membrane was incubated with detection solution for 
1 min. After incubation, detection solution was drained off and the membrane was 
covered with a plastic layer and placed in a cassette. The development of the film was 
carried out in a dark room. Therefore, a sheet of autoradiography film (FujiRX film) was 
put on top of the membrane and exposed for 10 sec. The film was developed and fixed 
immediately with an x-ray developer Curix 160 (Agfa-Gevaert). Depending on the 
intensity of the band, the second film was exposed either for a longer or shorter period of 
time. 
2.2.17 In vitro translation assay 
The in vitro translation assay was performed by using the Rabbit Reticulocyte Lysate 
system (Promega).  The amino acid mixtures, lacking Leucine and methionine were 
used in this reaction. By using both incomplete mixes, a sufficient concentration of all 
amino acids was obtained. Briefly, the following components were incubated:  
 
volume Reagents 
35 µl Rabbit Reticulocyte Lysate 
0.5 µl Amino acid mixture minus Leucine (1 mM) 
0.5 µl Amino acid mixture minus Methionine (1 mM) 
1 µl RNasin Ribonuclease Inhibitor (40 U/µl) 
1 µl Luciferase RNA (1 µg/µl) 
12 µl Nuclease-free water 
 
The reactions were incubated at 30ºC for the indicated time points and the synthesis of 
luciferase was assayed with a luminometer (Duolumat LB9507 Berthold). 
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2.3  Cellular biological methods 
2.3.1 Cell culture  
All cell culture work was done under sterile conditions. All cell lines were cultured at 
37°C in 5% CO2. Cells were grown as suspension cultures and maintained by the 
replacement of RPMI medium every third day of culture. Cell density was kept between 
1 x 105 and 4 x 105 cells/ml and counted with a Neubauer cell counting chamber.   
2.3.2 Storage of eukaryotic cell lines 
Cell freezing 
Cell lines were stored for a long-term use in liquid nitrogen or for a short-term use in a 
freezer at  -80ºC. For storages of cell lines, cells were centrifuged at 1500 rpm for 5 min. 
at 4ºC, resuspended in an adequate medium (1-2 x 106 cells/ml), supplemented with 
10% FCS and 10% DMSO. Additon of DMSO provides protection against formation of 
ice crystals inside the cells during the freezing procedure. After dispensing of cells into 2 
ml cryotubes, cell suspensions were transferred immediately into an -80ºC freezer for 
short-term storage and stored in liquid nitrogen (-196 ºC) for long-term storage. 
Cell thawing  
Frozen cells were thawed directly at 37ºC in a waterbath. Immediately after thawing, the 
cell solution was transferred into a 10 ml Falcon tube and resuspended in RPMI with 
10% FCS, and centrifuged at 1500 rpm for 5 min. The supernatant was discarded and 
cells were resuspended in 10 ml fresh pre-warmed RPMI with 10% FCS. 
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2.3.3 Apoptosis analysis 
Apoptotic cell death was examined by DNA fragmentation according to the method of 
Nicolletti (Nicoletti et al., 1991). Briefly, LZ-TRAIL, LZ-CD95L or drug-treated cells (1 x 
106) were collected by centrifugation at 1500 rpm for 5 min. The cells  were washed with 
200 µl PBS and centrifuged again at 1500 rpm for 5 min. The cells were lysed in 200 µl 
of a hypotonic fluorochrome solution containing propidium iodide and stored O/N at 4 ºC 
in dark. The propidium iodide stained DNA fragments were  quantified by flow cytometry 
(Becton Dickinson). Specific DNA fragmentation was calculated (percentage of 
experimental DNA fragmentation – percentage of spontaneous DNA fragmentation) / 
(100 – percentage of spontaneous DNA fragmentation) x 100%. 
2.3.4 Cell cycle analysis 
Drug-treated cells were collected and stained with Nicoletti lysis buffer as described in 
2.3.3. Quiescent and G1 cells have one copy of DNA and will therefore have 1X 
fluorescence intensity. Cells in G2/M phase of the cell cycle will have two copies of DNA 
and therefore, will have 2X intensity. Since the cells in S phase are synthesizing DNA, 
they will have fluorescence values between the 1X and 2X populations. The resulting 
histrogram consists of three populations: two Gaussian curves (1X and 2X peaks) and 
the S-phase population. Adjacent populations overlap each other. Therefore, a 
population of cells at different cell cycle state can be examined by measuring the 
amount of fluorescence-labelled DNA by flow cytometry.  
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2.3.5 Cell surface staining 
For analysis of the surface expression levels of TRAIL and CD95 receptors, cells (5 x 
105) were washed with PBS and incubated with 1 µg/mL of corresponding antibodies for 
30 min at 4°C, washed with PBS and incubated for 30 min with phycoerythrin-conjugated 
goat anti-mouse antibody (Dianova, Hamburg, Germany), and analyzed by flow 
cytometry with a FACScan Cytometer (Becton Dickinson). A minimum of 10 000 cells 
per sample was analyzed. For analysis of the TRAIL receptors the following antibodies 
were used: HS101 (TRAIL-R1), HS201 (TRAIL-R2), HS301 (Dc-R1), and HS402 (Dc-
R2) (mIgG1, Alexis, San Diego).  
2.3.6 Isolation of peripheral blood lymphocytes (PBL) 
Human peripheral blood lymphocytes (PBL) were isolated from heparinized blood of 
healty donors using standard Ficoll-Hypaque gradient centrifugation. Briefly, 30 ml blood 
was loaded gently on the surface of 15 ml Ficoll in a 50 ml Falcon tube, without 
disturbing the interphase and centrifuged at 20 ºC, 2420 g for 20 min. According to 
different sizes of blood cells, lymphocytes and myeloid cells formed a gradient band at 
the interphase. Cells at the interphase were collected and diluted with 1 volume of RPMI 
medium (without FCS) and then centrifuged at RT, 1500 rpm for 5 min. The cell pellets 
were resuspended in 15 ml of RPMI medium and incubated in a culture flask. The 
myeloid cells were removed from lymphocytes by incubation of the culture flask at 37 ºC 
for 1 hr (myeloid cells adhere on the surface of the flask). T lymphocytes were further 
purified from lymphocytes by a rosetting technique using sheep erythrocytes. Briefly, 8 x 
106 cells/ml were mixed with 1:1 volume of 2-amino-ethylisothyo-uronium-bromide-
treated (AET-) sheep erythrocytes. The T cells can be separated from the B cells by 
centrifugation at RT, 1000 rpm for 10 min. The supernatant containing the B cells was 
discarded and the pellet containg the T cells and sheep erythrocytes was suspended in 
4 volumes of ACK buffer to lyse the erythrocytes. Purified T cells were suspended at a 
concentration of 2 x 106 cells/ml.  
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2.3.7 Preparation of AET-sheep erythrocytes 
For preparation of a 2% erythrocyte solution, 25 ml of sheep erythrocytes were washed 
with sterile PBS for several times until the supernatant becomes clear. The erythrocytes 
were suspended in AET solution (0.5 g AET in 12.5 ml H2O (pH = 9.0)) and incubated at 
37 ºC on a roller for 15 min. The erythrocytes were then washed again with PBS until the 
supernatant becomes clear. The pellet containing the erythrocytes were then 
resuspended in RPMI at a concentration of 2% erythrocytes. The erythrocytes could be 
kept for three days at 4ºC.  
2.3.8 Transfection 
This transfection method is based on the fact that cell membranes can be made 
transiently permeable by the application of short electric pulses. A NF-ĸB luciferase 
reporter construct containing four copies of the NF-ĸB consensus binding site and a 
pcDNA3 expression plasmid containing the Tax cDNA were transiently transfected into 
Jurkat T cells by electroporation. Briefly, cells (5 x 106) suspended in 400 µl of FCS-free 
RPMI medium, mixed with plasmid DNA (5 µg/ml) and cooled on ice. Subsequently, 
cells were electroporated using a gene pulser (Bio-Rad) at 240 V / 950 µF with constant 
duration time of a pulse. The electroporated cells were plated out immediately mixed 
with an equal volume (400 µl) of fresh medium. Life cells were transferred into a 6 cm 
Petri dish containing 3.5 ml fresh medium. 
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2.3.9  Luciferase assay 
Jurkat T cells were transfected with reporter constructs and cultured O/N as described. 
Next day, the cells were centrifuged, washed with PBS and lysed in 50 µl of Passive 
Lysis Buffer (Promega) for 20 min on ice. The samples were centrifuged for 6000 rpm 
for 3 min and analyzed with a Luminometer (DuoLumat, Berthold). Therefore 2 x 10 µl 
aliquots were analyzed after adding 50 µl Luciferase-reagents in the reaction chamber 
and light emission was detected for 10 sec. The mean and the standard deviation was 
calculated out of two measurements and further analyzed.  
2.3.10 Metabolic labeling 
Protein synthesis was estimated by measuring the amount of incorporated 35S 
methionine. Briefly, cells (1 x 105) were incubated for 2 hr with 1 ml of methionine-free 
medium (Sigma) in a 24-wells plate. Then 10 µl pro well of 35S protein-labeling mix (7 
mCi (2.59MBq)) (Perkin Elmer) was added and cells were treated with different drugs as 
indicated. After incubation, cells were washed twice with PBS and lysed in ice-cold 
RIPA-lysis buffer for 15 min on ice and centrifuged (20 min, 13000 rpm). 4 µl of each 
lysate, was loaded on a filter paper, followed by precipitation with 10% Trichloroacetic 
Acid (TCA) by incubating the filter paper three times in TCA precipitation buffer for 5 
min. After drying, the filters papers were incubated in 1 ml of Liquid Scintillation Cocktail 
solution (Beckman coulter, CA) and radioactivity was determined with Liquid Scintillation 
counting. 
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3. RESULTS 
3.1  Molecular basis of apoptosis resistance of     
HTLV-1 infected T cells 
3.1.1 HTLV-1 infected T cells are relatively resistant to CD95-induced 
apoptosis  
Generally, deletion of virus infected cells by the immune system takes place by CD8+ 
cytotoxic T cells. One important mechanism, whereby CD8+ T cells kill virus infected 
cells is mediated by the CD95/CD95L system. However, HTLV-1 infected T cells were 
found to be resistant towards CD95-induced apoptosis (Copeland et al., 1994). A similar 
resistance was also observed in T cells derived from transgenic mice carrying the tax 
gene (Kishi et al., 1997). Analysis of these mice suggested that protection of peripheral 
T cells from CD95-induced apoptosis is one of the important underlying mechanisms 
leading to the immortalization of T cells. To further investigate the mechanism by which 
HTLV-1 infected T cells escape apoptosis, four HTLV-1 infected T cell lines, ATL-3, 
CHAMP, MT-2 and SP derived from HTLV-1 infected patients were examined for their 
sensitivity towards CD95-induced apoptosis. Cells were treated with different 
concentrations of recombinant LZ-CD95L or the agonistic antibody anti-APO-1 for 16 hr. 
Apoptotic cell death was examined by DNA fragmentation according to the method of 
Nicoletti (Nicoletti et al., 1991). Apoptotic cell death of the HTLV-1 infected T cell lines 
was compared with the control T cell lines CEM and Jurkat. After treatment with LZ-
CD95L (200 ng/ml), 65-75% of CEM and Jurkat underwent apoptosis, whereas only 25-
35% of the HTLV-1 infected T cells showed apoptotic cell death (Fig. 3.1A). Similar 
results were obtained upon treatment with anti-APO-1 (Fig. 3.1B). At a concentration of 
50 ng/ml anti-APO-1, the control T cell lines Jurkat and CEM underwent 70-85% 
apoptotic cell death but only 25-34% cell death was observed in the HTLV-1 infected T 
cell lines (Fig. 3.1B). This indicates that HTLV-1 infected T cell lines were more resistant 
towards CD95-induced apoptosis.  
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Figure 3.1: HTLV-1 infected T cells are relatively resistant towards CD95-
induced apoptosis.  
1 x 106 cells of the HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP and control 
T cell lines CEM and Jurkat were incubated with various concentrations of LZ-CD95L 
(50, 100, 200 ng/ml) (A) or anti-APO-1 (5, 25, 50 ng/ml) (B) for 16 hr. Apoptotic cell death 
was determined by Nicoletti staining. The data are representative of three independent 
experiments. 
 
3.1.2  HTLV-1 infected T cell are resistant towards TRAIL-induced 
apoptosis.  
Since HTLV-1 infected T cells were shown to be relatively resistant towards CD95-
induced apoptosis, we analysed whether these cells are more resistant towards death 
receptor-mediated apoptosis. To investigate this, TRAIL, was applied to the HTLV-1 
infected T cells. ATL-3, CHAMP, MT-2 and SP were treated with different concentrations 
of recombinant LZ-TRAIL for 16 hr and apoptotic cell death was examined by DNA 
 
69
Results 
fragmentation. The non-infected T cell lines CEM and Jurkat were used as control. The 
experiment showed that 35-55% of the control T cell lines CEM and Jurkat underwent 
apoptotic cell death after treatment with LZ-TRAIL (100 ng/ml). In contrast, only 4-8% 
apoptotic cell death was observed in HTLV-1 infected T cells (Fig. 3.2). Thus, HTLV-1 
infected T cells are not only resistant towards CD95L but also to TRAIL-induced 
apoptosis.  
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Figure 3.2: HTLV-1 infected T cells are resistant towards TRAIL-induced 
apoptosis.  
1x106 cells of the HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP and the 
control T cell lines CEM and Jurkat were incubated with various concentrations of 
recombinant LZ-TRAIL (0-100 ng/ml) for 16 hr. Apoptotic cell death was determined by 
DNA fragmentation. The data are representative of three independent experiments.
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3.1.3 Non-infected and HTLV-1 infected T cells express comparable 
amounts of CD95 and TRAIL receptors 
Resistance of HTLV-1 infected T cells towards CD95L- and TRAIL-induced apoptosis 
might be due to a lower level of receptor expression. To examine this assumption, 
surface expression levels of CD95 and different TRAIL receptors in the HTLV-1 infected 
T cell lines ATL-3, CHAMP, MT-2 and SP were compared with the control T cell lines 
CEM and Jurkat. The experiments showed that all four HTLV-1 infected T cell lines 
display a similar CD95 surface expression as compared to control T cell lines (Fig. 3.3).  
The difference in sensitivity towards CD95-induced apoptosis is therefore not due to a 
difference in surface expression of CD95.  
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Figure 3.3: Non-infected T cells and HTLV-1 infected T cells express 
comparable amount of CD95 
Cells (1x106) of the HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP and the 
non-infected T cell lines Jurkat and CEM were incubated with anti-APO-1 (1 µg/mL) or an 
IgG3 isotype control antibody for 30 min on ice.  CD95 surface expression was analyzed 
by flow cytometry. The data are representative of two independent experiments. 
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Four TRAIL receptors are expressed. TRAIL-R1 and TRAIL-R2 are death receptors that 
mediate TRAIL-induced apoptosis, whereas, Dc-R1 and Dc-R2 are believed to 
negatively regulate TRAIL-induced apoptosis by competing for ligand binding (Sheridan 
et al., 1997). Therefore, the surface expression levels of all four receptors were 
analyzed. Both, HTLV-1 infected and non-infected T cell lines express TRAIL death 
receptors, however there is no clear correlation between the expression levels of 
different TRAIL receptors and the sensitivity of these cell lines to TRAIL-induced 
apoptosis. For example, MT-2 cells express similar amounts of TRAIL-R1 and TRAIL-R2 
as Jurkat T cells. However, Jurkat T cells were sensitive whereas MT-2 cells were 
resistant to TRAIL-induced apoptosis (Fig 3.4). Furthermore, CHAMP expresses the 
decoy receptor Dc-R2 at a similar level as the decoy receptor Dc-R1 in Jurkat T cells. In 
contrast to Jurkat T cells, CHAMP cells were resistant to TRAIL-induced apoptosis. The 
data indicate that resistance of HTLV-1 infected T cells to death receptor-mediated 
apoptosis is not due to the lack of surface expression of death receptors or upregulation 
of decoy receptors.  
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Figure 3.4: Surface expression of different TRAIL receptors in HTLV-1 
infected T cells and control T cell lines.  
Surface expression of TRAIL-R1, TRAIL-R2, the decoy receptors Dc-R1 and Dc-R2 in 
HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP were compared with that in 
control T cell lines CEM and Jurkat. Cells were analyzed with HS101 (TRAIL-R1), HS201 
(TRAIL-R2), HS301 (Dc-R1), HS402 (Dc-R2) for surface expression of different TRAIL 
receptors or an IgG1 isotype control antibody. The data are representative of two 
independent experiments. 
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3.1.4 HTLV-1 infected T cells express elevated amounts of c-FLIP 
The basis of apoptotic resistance in HTLV-1 infected T cells has been partly explained 
by dysregulated expressions of proteins involved in the cell death pathway. The anti-
apoptotic Bcl-2 family protein Bcl-XL and Bcl-2 have been shown to be up-regulated in 
HTLV-1 infected T cells (Mori et al., 2001). However, Bcl-2 and Bcl-XL are considered to 
mainly regulate apoptosis at the mitochondrial level. In our previous work CD95-induced 
apoptosis was found to be blocked at the DISC level upstream of caspase-8 in HTLV-1 
infected T cells (Krueger et al., 2006). The only molecule known to inhibit CD95 and 
TRAIL signaling at the DISC level is c-FLIP. Therefore, we compared c-FLIP expression 
levels of HTLV-1 infected T cells with that of control T cells. As controls, expression 
levels of pro-caspase-8 and tubulin were analyzed. Western blot analysis revealed that 
all four Tax-expressing HTLV-1 infected T cell lines express increased levels of both c-
FLIP isoforms, c-FLIPS and c-FLIPL (Fig. 3.5). Consistent with the previous reports, Bcl-
2 and Bcl-XL expression were shown to be also increased in HTLV-1 infected T cells. In 
previous experiments, we have shown that the elevated expression of c-FLIP is 
regulated by the Tax protein. Activation of Tax in an inducible system led to both 
resistance towards CD95-induced apoptosis and an increased expression of c-FLIP. 
Downregulation of c-FLIP expression by using siRNA abolished apoptosis resistance of 
the HTLV-1 infected T cells (Krueger et al., 2006). 
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Figure 3.5: HTLV-1 infected T cells express increased amounts of c-FLIP.  
c-FLIP levels in HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP and non-
infected T cell lines Jurkat and CEM were analyzed by Western blot with antibodies 
against c-FLIP, Bcl-XL, Bcl-2, Bad,  pro-caspase-8 and the viral protein Tax. Tubulin 
levels served as a control for equal loading of proteins. The data are representative of 
two independent experiments. 
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3.2 Sensitization of HTLV-1 infected T cells towards 
death receptor-mediated apoptosis by 
Rocaglamide 
3.2.1 Chemical structure of the Rocaglamide derivative Roc-AR 
Recently, our group showed that Roc derivatives can induce apoptosis in different 
leukemia cell lines and in leukemia cells freshly isolated from patients, but not in normal 
peripheral blood lymphocytes (Zhu et al., 2007). The low toxicity of Rocaglamide in 
normal lymphocytes prompts us to investigate whether these compounds can induce 
apoptosis in HTLV-1 infected T cells and whether they can sensitize HTLV-1 infected T 
cells. Therefore we tested one of these derivatives, 1-oxo-11,12-methylendioxy-rocglaol, 
abbreviated as Roc-AR (Fig. 3.6) on the CD95L- and TRAIL- resistant HTLV-1 infected 
T cell lines. For all experiments, Roc-AR was used at a purity of at least 98% (Baumann 
et al., 2002). 
 
 
 
 
 
 
 
Figure 3.6: Chemical structure of the Rocaglamide derivative, 1-oxo-11, 12-
methylendioxy-rocglaol (Roc-AR).
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3.2.2 Roc-AR sensitizes HTLV-1 infected T cell lines towards CD95L 
and TRAIL-induced apoptosis 
To study the effect of Roc-AR on HTLV-1 infected T cells, ATL-3, CHAMP, MT-2 and SP 
were treated with Roc-AR alone or in combination with LZ-CD95L. Apoptotic cell death 
was examined by DNA fragmentation. The experiment showed that 5-15% of the cells 
underwent apoptotic cell death after treatment for 16 hr with 100 nM Roc-AR alone and 
2-10% apoptotic cell death after treatment with LZ-CD95L. However, treatment in 
combination of Roc-AR and LZ-CD95L resulted in a significant increase in apoptosis 
(30-50%) (Fig. 3.7). 
0
10
20
30
40
50
ATL-3 CHAMP MT-2 SP
S
pe
ci
fic
 D
N
A 
fra
gm
en
ta
tio
n 
(%
)
LZ-CD95L Roc-AR LZ-CD95L / Roc-AR
S
pe
ci
fic
 D
N
A 
fra
gm
en
ta
tio
n 
(%
)
 
Figure 3.7: Roc-AR sensitizes HTLV-1 infected T cell lines towards CD95-
induced apoptosis. 
1 x 106 cells of the HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP were left 
untreated or were treated either with LZ-CD95L (100 ng/ml) or Roc-AR (100 nM) alone or 
in combination for 16 hr. The results shown are representative of three independent 
experiments. 
 
To investigate whether Roc-AR can also sensitize TRAIL-mediated apoptosis, different 
HTLV-1 infected cell lines were treated with LZ-TRAIL (100 ng/ml), Roc-AR (100 nM) 
alone or in combination. The experiment showed that 1-5% of the cells underwent 
apoptotic cell death after treatment for 16 hr with LZ-TRAIL alone and 8-12% apoptotic 
cell death with Roc-AR alone. However, the combination of Roc-AR and LZ-TRAIL 
resulted in 26-50% apoptotic cell death (Fig. 3.8). These data indicate that Roc-AR can 
sensitize HTLV-1 infected T cell lines towards CD95- and TRAIL-induced apoptosis. 
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Figure 3.8: Roc-AR sensitizes HTLV-1 infected T cell lines towards TRAIL-
induced apoptosis. 
1 x 106 cells of the HTLV-1 infected T cell lines ATL-3, CHAMP, MT-2 and SP were 
treated with either LZ-TRAIL (100 ng/ml) or Roc-AR (100 nM) alone or in combination for 
16 hr. The results shown are representative of three independent experiments. 
 
3.2.3  Roc-AR enhances CD95L and TRAIL induced caspase 
processing 
Processing and activation of pro-caspase-8 is one of the earliest events after death 
receptor triggering. Activation of pro-caspase-8 is followed by processing and activation 
of downstream effector pro-caspase-3. To confirm the sensitization towards CD95L and 
TRAIL mediated cell death by Roc-AR via the extrinsic cell death pathway, we analyzed 
processing of pro-caspase-8 and pro-caspase-3. The HTLV-1 infected T cell lines SP 
and MT-2 were treated either with LZ-CD95L (100 ng/ml), LZ-TRAIL (100 ng/ml) or Roc-
AR (100 nM) alone, or in combination for 4 hr processing of pro-caspase-8 and pro-
caspase-3 was analyzed by Western blot. The experiment showed that treatment with 
Roc-AR enhanced LZ-CD95L- and LZ-TRAIL-induced cleavage of caspase-8 and 
consequently, enhanced cleavage of caspase-3 (Fig. 3.9). These findings further 
demonstrate that Roc-AR can sensitize HTLV-1 infected T cell lines towards CD95L and 
TRAIL-induced apoptosis via the extrinsic cell death pathway.  
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Figure 3.9: Roc-AR enhances LZ-CD95L and LZ-TRAIL induced caspase 
processing. 
Cells (1 x 107) of the HTLV-1 infected T cell lines SP (A) and MT-2 (B) were left untreated 
or were treated with either LZ-CD95L (100 ng/ml), LZ-TRAIL (100 ng/ml) or Roc-AR (100 
nM) alone or in combination as indicated for 4 hr. Analysis of tubulin expression served 
as control for equal protein loading. The results shown are representative of three 
independent experiments. 
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3.2.4  Roc-AR does not sensitize CD95L- and TRAIL-induced apoptosis 
in normal T cells 
For therapeutic means, Roc-AR should have low toxicity on normal T cells. Therefore, 
the effect of Roc-AR on peripheral blood T cells was analyzed. Freshly isolated 
peripheral blood T cells from three healthy donors were incubated with LZ-CD95L (100 
ng/ml), LZ-TRAIL (100 ng/ml) or Roc-AR (100 nM) alone, or in combinations for 16 hr. 
Cells were harvested and apoptotic cell death was examined by DNA fragmentation. In 
contrast to HTLV-1 infected SP cells, only 2-10% of healthy blood T cells underwent  
apoptotic cell death after treatment in combination with Roc-AR (Fig. 3.10). These data 
suggest that Roc-AR does not enhance CD95L- and TRAIL-induced apoptosis in freshly 
isolated T cells. 
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Figure 3.10: Roc-AR does not sensitize CD95- and TRAIL-induced apoptosis 
in normal T cells. 
Freshly isolated peripheral blood T cells (1 x 106 cells) from three healthy donors were 
left untreated or were treated with Roc-AR (100 nM) alone or in combination with A) LZ-
CD95L (100 ng/ml) or B) LZ-TRAIL (100 ng/ml) for 16 hr. HTLV-1 infected T cell line SP 
was used as control. The data are representative of three independent experiments. 
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3.3. Molecular mechanisms of Roc-AR-induced             
sensitization of death receptor-mediated 
apoptosis  
3.3.1  Roc-AR does not affect CD95 or TRAIL receptor expression 
levels 
Previous findings have shown that certain drugs induce upregulation of CD95 or TRAIL 
receptor expression and thereby sensitize cancer cells towards receptor-mediated 
apoptosis (Ganten et al., 2005). To examine this possibility, the effect of Roc-AR on 
expression of CD95 and the different TRAIL receptors was investigated. HTLV-1 
infected T cell lines ATL-3, CHAMP, MT-2 and SP were treated with Roc-AR for 12 hr 
and surface expression of different receptors was analyzed by flow cytometry. No 
upregulation of surface expression of CD95 or TRAIL receptors could be observed in 
any of the cell lines tested (Fig. 3.11 and 3.12). Kinetic analysis of CD95 and TRAIL 
receptor surface expression levels after 2 hr to 24 hr Roc-AR treatment also showed no 
upregulation (data not shown). These experiments demonstrate that Roc-induced 
sensitization is not mediated by an upregulation of death receptors on the cell surface. 
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Figure 3.11: Roc-AR does not alter CD95 surface expression in HTLV-1 
infected T cell lines.  
Untreated or Roc-AR (100 nM for 12 hr) treated cells (1 x 106) of the HTLV-1 infected T 
cell lines ATL-3, CHAMP, MT-2 and SP were stained with anti-APO-1 (1 µg/mL) or an 
IgG3 isotype control antibody for detection of CD95 surface expression. The data are 
representative of two independent experiments. 
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Figure 3.12: Roc-AR does not alter TRAIL receptor surface expression in 
HTLV-1 infected T cell lines.  
Untreated or Roc-AR (100 nM for 12 hr) treated cells (1 x 106) of the HTLV-1 infected T 
cell lines ATL-3, CHAMP, MT-2 and SP were analyzed with HS101 (TRAIL-R1), HS201 
(TRAIL-R2), HS301 (Dc-R1), and HS402 (Dc-R2)  or an IgG1 isotype control antibody for 
detection of TRAIL surface expression. The data are representative of two independent 
experiments. 
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3.3.2  Roc-AR sensitizes HTLV-1 infected T cells via suppression of the 
anti-apoptotic protein c-FLIP 
Next we analyzed alterations of the apoptotic signaling pathways upon Roc-AR 
treatment. As shown before, HTLV-1 infected T cells contain a strongly elevated 
expression of c-FLIP, which is critical for the sensitivity towards CD95L and TRAIL-
induced apoptosis (Fig. 3.5 and Krueger et al., 2006). Therefore, the expression level of 
c-FLIPL and c-FLIPS were analyzed after Roc-AR treatment. SP and CHAMP T cell line 
were treated with Roc-AR (100 nM) for various time periods (Fig. 3.13A) and 
concentrations of Roc-AR for 4 hr (Fig. 3.13B). c-FLIP expression was analyzed by 
Western blot. As shown, treatment with Roc-AR resulted in a strong decrease in 
expression of both isoforms of c-FLIP which could be detected as early as 2 hr after 
stimulation. The decrease in c-FLIP expression by Roc-AR was mediated in a dose-
dependent way. In contrast, expression of pro-caspase-8 was not altered by Roc-AR 
treatment. Taken together, these results imply that loss of expression of c-FLIPL and c-
FLIPS was responsible for the sensitization of HTLV-1 infected T cells towards CD95L 
and TRAIL-induced apoptosis. 
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Figure 3.13: Roc-AR inhibits the expression of c-FLIP. 
1 x 107 cells of the HTLV-1 infected T cell line SP and CHAMP were left untreated or 
were treated with Roc-AR (100 nM) for up to 32 hr (A) or were treated with various 
concentrations of Roc-AR (5, 20, 50, 100, 200 nM) for 4 hr (B). Cells were lysed and 20 
µg of soluble protein was separated by SDS-PAGE. Protein levels were analyzed by 
Western blot with antibodies against c-FLIP and caspase-8. Tubulin expression served 
as a control for equal protein loading. 
 
3.3.3  Roc-AR does not suppress c-FLIP expression by affecting the 
viral Tax protein  
We have previously shown that in HTLV-1 infected T cells c-FLIP expression levels are 
increased by the HTLV-1 transactivator protein Tax (Krueger et al., 2006). Therefore, 
decrease in c-FLIP protein expression could be due to a Roc-AR mediated decrease in 
Tax protein levels. To examine this possibility, the HTLV-1 infected T cell line SP was 
incubated with Roc-AR (100 nM) for different time periods and the Tax expression levels 
were analyzed by Western blot. As shown in Fig. 3.14, Roc-AR did not alter the Tax 
protein expression, whereas c-FLIP expression was decreased. Therefore, the decrease 
in c-FLIP protein levels after treatment with Roc-AR is Tax-independent. 
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Figure 3.14: Roc-AR does not suppress expression of the viral Tax protein. 
HTLV-1 infected T cell line SP (1 x 107) was left untreated or was incubated with Roc-AR 
(100 nM) for up to 32 hr. Cells were lysed and 20 µg of soluble protein were separated by 
SDS-PAGE. Protein level was analyzed by Western blot with antibodies against c-FLIP, 
pro-caspase-8 and Tax. Tubulin expression served as control for equal protein loading. 
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3.3.4  HTLV-1 infected T cells do not show increased nuclear 
localization of NFAT 
In previous studies, our group showed that rocaglamide derivatives can suppress NFAT 
activation in T cells at concentrations of 25-100 nM without affecting other transcription 
factors such as NF-ĸB (Proksch et al., 2005). It has been reported that NFAT is 
constitutively activated in HTLV-1 infected T cells (Good et al., 1996). Furthermore, it 
has been reported that c-FLIP expression is regulated by the transcriptional activity of 
NFAT (Good et al., 1996; Rivera et al., 1998). This prompted us to investigate whether 
the decrease in c-FLIP expression is the consequence of downregulation of NFAT 
activity. Therefore, the activation status of NFAT in HTLV-1 infected T cells was 
examined by Western blot. Nuclear extracts were prepared from the HTLV-1 infected T 
cell lines CHAMP, MT-2 and SP and compared with non-infected T cell lines Jurkat 
(non-stimulated or PMA/Ionomycin (PMA/I) stimulated).  Jurkat T cells show an increase 
in nuclear localization of NFAT upon treatment with PMA/I. However, no substantial 
increase in nuclear localization of NFAT in HTLV-1 infected T cells as compared with 
Jurkat T cells was seen (Fig. 3.14). This would indicate that NFAT is not constitutively 
activated in the studied HTLV-1 infected T cell lines.  
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Figure 3.14: No detectable increase in nuclear localization of NFAT in HTLV-
1 infected T cell lines as compared with non-infected Jurkat T cells.  
Nuclear extracts were prepared from 1x108 cells from HTLV-1 infected T cell lines MT-2, 
SP and CHAMP or Jurkat cells untreated or treated  for 2 hr with PMA (100 ng/ml) / 
Ionomycin (1 µM). From each sample, 20 µg of nuclear protein was separated by SDS-
PAGE and NFAT level was analyzed by Western blot. NF-Y expression served as control 
for equal protein loading.  
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3.3.5  NFAT inhibitor CsA does not affect c-FLIP mRNA transcription 
NFAT activity can be inhibited by the calcineurin inhibitor cyclosporin A (CsA). To further 
analyze whether inhibition of c-FLIP protein expression by Roc-AR was mediated by 
blocking the transcriptional activity of NFAT, the HTLV-1 infected cell line SP was 
treated with the NFAT inhibior CsA. mRNA analysis showed that the expression levels of 
c-FLIP were not affected by CsA (Fig. 3.15). These results imply that NFAT is at least 
not critically involved in the decrease of c-FLIP expression in HTLV-1 infected T cells 
after Roc-AR treatment.  
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Figure 3.15: No influence of CsA on c-FLIP transcription.  
HTLV-1 infected T cell line SP was treated with CsA (100 ng/ml) for the indicated time 
and mRNA expression levels of c-FLIPS and c-FLIPL were analyzed by RT-PCR. One 
representative experiment of two is shown.  
 
 
3.3.6 Roc-AR does not sensitize HTLV-1 infected T cells towards 
apoptosis by inhibiting the transcription factor NF-ĸB 
In freshly isolated ATL cells and HTLV-1-transformed T cells, NF-ĸB has been found to 
be constitutively activated (Ballard et al., 1988; Ruben et al., 1988; Leung et al., 1988). It 
has been reported that Tax-mediated increase in c-FLIP expression partially involves 
NF-κB activation (Yonehara et al., 2006). Rocaglamide derivatives were reported to 
have a suppressive effect on TNFα- and PMA-induced NF-кB activity (Baumann et al., 
2002).  In contrast, our group has shown that Rocaglamide derivatives have no effect on 
NF-кB activity when applied at concentrations of 50-100 nM (diploma thesis, Zhu). To 
investigate whether the observed decrease in c-FLIP expression by Roc-AR is mediated 
through downregulation of NF-ĸB activity, the status of NF-κB activity in HTLV-1 infected 
T-cell lines was analyzed. Nuclear extracts were prepared from the HTLV-1 infected T 
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cells lines MT-2, SP and CHAMP and the nuclear localization of the NF-ĸB subunits p50 
and Rel A was compared with PMA/Ionomycin stimulated Jurkat T cells by Western blot. 
Consistent with the previous publications, HTLV-1 infected T cells showed a constitutive 
nuclear expression of p50 and Rel A, whereas Jurkat T cells showed nuclear localization 
of these subunits only after stimulation with PMA/Ionomycin (Fig 3.16A). Next, to 
investigate whether Roc-AR inhibits the NF-ĸB pathway and thereby decreases c-FLIP 
protein expression, the HTLV-1 infected T cell line SP was treated with different 
concentrations of Roc-AR for 4 hr and nuclear extracts were prepared and analyzed by 
Western blot. Treatment with Roc-AR up to 200 nM showed no decrease in nuclear 
localization of p50 and RelA in cell line SP, which indicates that NF-κB activity is not 
altered by Roc-AR treatment (Fig. 3.16B). 
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Figure 3.16: Roc-AR does not sensitize HTLV-1 infected T cell lines by 
inhibition of NF-ĸB activity 
A) Nuclear localization of p50 and Rel A in HTLV-1 infected T cells. Nuclear extracts from 
1 x 108 HTLV-1 infected T cell lines MT-2, SP, CHAMP, untreated or treated Jurkat cells 
(PMA (100 ng/ml) /I (1 µM) for 2 hr) were subjected to Western blot analysis. From each 
nuclear lysate, 20 µg of nuclear protein was separated by SDS-PAGE and analyzed with 
antibodies against p50 and Rel A. NF-Y expression served as control for equal protein 
loading. B) No Inhibition of nuclear localization of NF-ĸB subunits p50 and Rel A by 
treatment with Roc-AR. HTLV-1 infected T cell line SP (1 x 108 cells) was left untreated 
or was incubated with different concentrations of Roc-AR for 4 hr (25, 50, 100 or 200 nM) 
and analyzed as in A. 
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3.3.7 Roc-AR does not inhibit c-FLIP at the transcriptional level  
NF-кB and NFAT are the two major transcription factors that have been reported to 
activate c-FLIP transcription. However, the above shown experiments do not support 
that Roc-AR suppresses c-FLIP expression by inhibition of NF-кB or NFAT. To 
investigate whether Roc suppresses c-FLIP expression at the transcriptional level, c-
FLIP mRNA was analyzed after Roc-AR treatment. The HTLV-1 infected T cell line SP 
was treated with Roc-AR (100 nM) and total RNA was isolated at the indicated time. The 
mRNA transcription levels of c-FLIPS and c-FLIPL were analyzed by RT-PCR.  
Analysis showed that c-FLIP mRNA expression levels were not altered after Roc-AR 
treatment (3.17A). To further confirm this result, c-FLIPS mRNA was analyzed after 
treatment with Roc-AR (100 nM) by quantitative real time PCR (3.17B). Again, no 
inhibition of c-FLIPS transcription could be detected. Taken together, these data show 
that the decrease in c-FLIP protein expression after Roc-AR treatment is not detectable 
at the transcriptional level. 
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Figure 3.17: Roc-AR does not inhibit c-FLIP expression at the transcriptional level 
A) HTLV-1 infected T cell line SP (1 x 108 cells) was treated with Roc-AR (100 nM) for the 
indicated time and mRNA expression levels of c-FLIPS and c-FLIPL were analyzed by RT-PCR. 
β-actin mRNA levels were analyzed as control. 
B) HTLV-1 infected T cell line SP (1 x 108 cells) was left untreated or treated with Roc-AR (100 
nM) for the indicated time and mRNA expression level of c-FLIPS was analyzed by quantitative 
real-time PCR. For both experiments, one representative experiment of two is shown.  
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3.3.8 Roc-AR inhibits protein expression at the translational level 
To further investigate the mechanism by which Roc-AR down-regulates c-FLIP 
expression, the effect of Roc-AR on protein synthesis was examined. As a positive 
control, the well known protein synthesis inhibitor cycloheximide (CHX) was used in 
parallel. The HTLV-1 infected T cell line SP was incubated for 2 hr with methionine-free 
medium. Then 35S-labelled methionine was added and cells were left untreated or were 
treated for 1 hr with different concentrations of Roc-AR (25-400 nM) or CHX (25-400 
ng/ml) or incubated for different periods of time up to 4 hr with Roc-AR (100 nM) or CHX 
(100 ng/ml) as indicated.  
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Figure 3.18: Roc-AR inhibits protein synthesis. 
SP cells (1 x 105)  were incubated with 35S-labelled methionine for 1 hr as described in 
materials and methods and were then left untreated or treated with Roc-AR (100 nM) or 
CHX (100 ng/ml) for indicated times (A) or with different concentration for 1 hr (B). Data 
are representative of two experiments. 
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As shown in Fig. 3.18A, CHX inhibited protein synthesis with an IC50 of 25 ng/ml. An 
almost complete block of protein synthesis could be observed at a concentration of 100 
ng/ml. Roc-AR inhibited protein synthesis with an IC50 of approximately 30 nM and  
almost completely inhibited protein synthesis at 100 nM (Fig. 3.18B). These data 
indicate that Roc-AR affects protein synthesis and thereby decreases c-FLIP protein 
expression.  
 
3.3.9 Roc-AR inhibits protein expression upstream of the translation 
machinery  
In order to investigate, whether Roc-AR inhibits protein synthesis on the translation 
level, the effect of Roc-AR on protein synthesis was studied by an in vitro translation 
system. The cell free rabbit reticulocyte lysate was incubated with luciferase mRNA in 
the absence or presence of different concentrations of Roc-AR (0-200 nM) or CHX (0-
200 ng/ml). Synthesis of luciferase protein was quantified by luminescense. Similar to 
the [35S]-methionine incorporation assay, there was a complete block of protein 
translation with CHX treatment at a concentration of 100 ng/ml (Fig. 3.19A). Surprisingly, 
100 nM of Roc-AR, which was shown to completely block protein translation in the 
incorporation assay, showed no effect on protein translation in this in vitro system.  
Kinetics also showed also no inhibition of protein translation in the in vitro system 
(3.19B). The experiment indicates that Roc-AR is affecting protein translation only in 
living cells and probably acts upstream of the translation machinery. 
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Figure 3.19: Roc-AR does not inhibit protein translation in vitro  
The cell-free rabbit reticulocyte in vitro translation assay was performed in the absence 
or presence of the indicated concentration of Roc-AR or CHX for 60 min (A) or with Roc-
AR (100 nM) and CHX (100 ng/ml) for the indicated time (B). Firefly luciferase activity 
(RLU) was measured as described in "Materials and methods". Error bars are ± SD for 
duplicate samples. Data are representative of triplicate experiments. 
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3.3.10 Roc-AR does not inhibit the Akt-mTOR pathway 
Initiation of translation in vivo involves a highly regulated process which requires several 
initiation factors, initiation complexes, and their inhibitors (Gingras et al., 1999b). The 
rate-limiting step is the binding of the initiation factor eIF4E to the mRNA 5' cap structure 
(Duncan et al., 1987; Sonenberg 1996). The activity of eIF4E is regulated by signaling 
pathways upstream of the protein translation machinery (Kleijn et al., 1998). One of the 
signaling pathways known to regulate eIF4E is the phosphatidylinositol 3-kinase 
(PI3K/Akt) pathway and its downstream target, the kinase mammalian target of 
rapamycin (mTOR) (Sonenberg, 1996). mTOR activation disrupts the interaction 
between 4E-BP1 and eIF4E, allowing eIF4E to bind to the 5’cap structure. Rapamycin 
treatment inhibits mTOR activation and thereby increases the interaction between eIF4E 
and 4E-BP, and consequently inhibits cap-dependent translation. To investigate whether 
Roc-AR might also interfere with this pathway and thereby block the initation of 
translation, the HTLV-1 infected T cell line SP was treated with Roc-AR (100 nM) and 
the phosphorylation status of mTOR and its downstream target kinase, S6 was analyzed 
by Western blot. As control, cells were treated with 100 ng/ml rapamycin. As shown, 
phosphorylation of the kinase mTOR and the downstream kinase S6 was blocked after 
treatment with Rapamycin in a time-dependent way (Fig. 3.20A).  However, 
phosphorylation was not inhibited or even seemed to be increased after Roc-AR 
treatment (Fig. 3.20B). These results suggest that Roc-AR does not inhibit the activation 
of the mTOR pathway. 
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Figure 3.20: Roc-AR does not affect the mTOR pathway. 
The HTLV-1 infected T cell line SP (1x107) was left untreated or was incubated with A) 
Roc-AR (100 nM) or B) rapamycin (100 ng/ml) for up to 120 min. Phosphorylation status 
of the mTOR pathway was analyzed by Western blot with antibodies against mTOR and 
S6. Tubulin expression served as control for equal protein loading. Data are 
representative of two reproducible experiments. 
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3.3.11 Roc-AR blocks the ERK-Mnk1-eIF4E pathway 
Besides the mTOR pathway, the activity of eIF4E is also known to be regulated by the 
ERK pathway. ERK phosphorylates the kinase Mnk, which in turn phosphorylates eIF4E. 
Phosphorylation of eIF4E increases its affinity for the 5’ cap structure and thereby 
stimulates translation. To investigate whether Roc-AR could block the ERK pathway, the 
phosphorylation status of Mek1/2, ERK, Mnk1, and eIF4E after Roc-AR treatment was 
analyzed by Western blot. As shown, treatment with 100 nM Roc-AR resulted in 
inhibition of Mek1/2, ERK, Mnk and eIF4E activation, which could be detected as early 
as 30 min (Fig 3.21). The results suggest that Roc-AR interferes with the ERK signal 
pathway, and, in this way, might influence the activitiy of eIF4E. 
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Figure 3.21: Roc-AR blocks the ERK-Mnk1-eIF4E pathway. 
HTLV-1 infected T cell line SP (1x107) was left untreated or was incubated with Roc-AR 
(100 nM) for 0-120 min. The phosphorylation status of ERK pathway kinases was 
analyzed by Western blot with antibodies against Mek, ERK, Mnk and eIF4E. Tubulin 
expression served as control for equal protein loading. Data are representative of two 
experiments. 
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3.3.12 Roc-AR arrests the cell cycle at the G1 phase 
De novo protein synthesis plays a critical role in the regulation of cell cycle progression, 
especially the transition from the G1 to the S phase (Mathews et al., 2000). Therefore 
the effect of Roc-AR on the different phases of the cell cycle was analyzed. HTLV-1 
infected T cell lines ATL-3, CHAMP, MT-2 and SP were treated with Roc-AR (100 nM) 
for 24 hr and cell cycle was analyzed by flow cytometry. As shown, treatment with 100 
nM Roc-AR, resulted in a decrease of S phase cells from 30% to 7%. G1 phase cells 
increased from 49 % to 77% (Fig. 3.22A). Similar results were observed with ATL-3, 
CHAMP and MT-2 cells after Roc-AR treatment (Fig. 3.22B). 
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Figure 3.22: Roc-AR arrests cell cycle at G1 phase 
Cell cycle analysis of HTLV-1 infected T cell lines MT-2, ATL-3, CHAMP and SP after 
treatment with 100 nM Roc-AR for 24 hr. 1 x 106 cells of each cell line were stained with 
Nicoletti buffer and the cellular DNA content was analyzed by flow cytometry. Data are 
analyzed with the program ModFit and are representative of three individual experiments. 
Increased G1-phase is marked by black boxes and decreased S phase is marked by red 
boxes.  
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3.3.13 HTLV-1 infected T cells express elevated levels of cyclin D1 and 
D2 
Cell cycle progression is regulated by CDKs and their regulatory subunits, cyclins 
(Cheng et al., 1998; Klippel et al., 1998). HTLV-1 infected T cell lines were reported to 
have an accelerated progression into S-phase (Lemoine et al., 2001). The transition of 
G1 to S phase is regulated by the D-type cyclins. Cyclin D2 was reported to be 
upregulated in HTLV-1 infected T cells by the protein Tax (Santiago et al., 1999). 
Therefore, the protein expression levels of the major cyclins in the HTLV-1 infected T 
cell lines ATL-3, CHAMP, MT-2 and SP were analyzed by Western blot. Compared with 
the control T cell lines CEM and Jurkat, HTLV-1 infected T cell lines show high 
expression of cyclin D1 and D2 but similar comparable levels of cyclin B and E (Fig 
3.23).  
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Fig 3.23 HTLV-1 infected T cells express elevated levels of cyclin D1 and D2 
Expression of cyclins in HTLV-1 infected T cells (ATL-3, CHAMP, MT-2 and SP) as 
compared with the non-infected T cell lines (Jurkat, CEM). Cells (1 x 107) were lysed and 
20 µg of soluble protein was separated by SDS-PAGE. Protein expression was analyzed 
by Western blot with antibodies against cyclin D1, D2, cyclin E and cyclin B. Tubulin 
expression served as control for equal protein loading. All data are representative of two 
reproducible experiments. 
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3.3.14 Roc-AR inhibits cyclin D1 and D2 protein expression 
To investigate the antiproliferation activity of Roc-AR, the effect of Roc-AR on cyclins 
was analyzed. The HTLV-1 infected T cell line SP was treated with 100 nM Roc-AR, and 
protein expression of the cyclins D1, D2, B and E was analyzed by Western blot. As 
shown in Fig 3.23, protein levels of cyclin D1 and D2 was decreased after 2 hr of Roc-
AR treatment whereas the other cyclins were not affected (Fig. 3.23). These data 
demonstrate that Roc inhibits D1 and D2 expression which led to cell cycle arrest at the 
G1 phase. 
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Figure 3.23: Roc-AR inhibits cyclin D1 and D2 expression.  
1x107 cells of the HTLV-1 infected T cell line SP were treated with 100 nM Roc-AR for 
the indicated time. Cells were lysed and 20 µg of soluble protein was separated by SDS-
PAGE. Protein level was analyzed by Western blot with antibodies against cyclin D1, D2, 
cyclin E and cyclin B. Tubulin expression served as control for equal protein loading. All 
data are representative of two reproducible experiments. 
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4 DISCUSSION 
4.1 Molecular basis of Apoptosis Resistance of  
HTLV-1 infected T cells 
HTLV-1 infection is causative for Adult T-Cell Leukaemia/Lymphoma (ATL) (Yoshida et 
al., 1982), a malignancy of clonal proliferation of infected mature CD4+ T-cells.  
HTLV-1 infection might lead to transformation of HTLV-1 infected cells and ultimately to  
development of ATL. The HTLV-1 Tax protein is required for the transformation events 
by interfering with processes that regulate DNA repair, cell cycle and apoptosis 
(Matsuoka and Jeang, 2005). For example, Tax abrogates DNA repair functions by 
inhibiting the expression of the DNA polymerase β, which is essential for base excision 
repair (BER) (Jeang et al., 1990; Philpott and Buehring, 1999), nucleotide excision repair 
(NER) (Kao et al., 2001) and mismatch repair (MMR) (Morimoto et al 2005). 
Furthermore, Tax stimulates proliferative factors that increase cell-cycle progression, 
especially at the G1–S-phase transition (Neuveut et al., 1998; Schmitt et al., 1998). Tax 
increases cyclin D2 expression by direct activation of the promoter (Santiago et al., 
1999). Tax also interacts and thereby activates the cyclin-dependent kinases (CDKs) 
CDK4 and CDK6 (Haller et al., 2002; Fraedrich et al., 2005), leading to hyper-
phosphorylation of retinoblastoma (RB) protein. The phosphorylation followed by 
degradation of RB releases transcription factor E2F1 (Schmitt et al., 1998; Iwanaga et 
al., 2001), accelerating cell-cycle transition from G1 to S phase.  
Tax is also known to interfere with the regulation of apoptosis. Elimination of virus 
infected T cells by the CD95/CD95L system is an important mechanism for killing of 
infected cells by CD8+ cytotoxic T cells. Recent studies have found that the frequency, 
diversity and function of HTLV-1 specific CD8+ cytotoxic T-cells are reduced in ATL 
patients as compared with healthy donors (Kozako et al., 2006). In addition, 
accumulating evidence showed that HTLV-1 infected T cells are resistant towards 
CD95-induced apoptosis (Copeland et al., 1994). Resistance towards CD95-induced 
apoptosis was also observed in T cells derived from transgenic mice carrying the viral 
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tax gene (Kishi et al., 1997). Analyses of these mice suggested that protection of 
peripheral T cells from CD95-induced apoptosis is one of the important underlying 
mechanisms required for the immortalization of T cells and the development of ATL. Our 
group previously investigated the molecular mechanisms of resistance mediated by 
HTLV-1 Tax. Our data showed that HTLV-1 infected T cell lines were resistant towards 
LZ-CD95L- and anti-APO-1-induced apoptosis (Fig. 3.1; Krueger et al., 2006). In this 
study we show that HTLV-1 infected T cells are also resistant towards TRAIL, which 
would suggest a general mechanism of resistance towards death receptor mediated 
apoptosis (Fig. 3.2). Multiple mechanisms might be involved in resistance to CD95L and 
TRAIL-mediated apoptosis (O’Connell et al., 1996; Whiteside and Rabinowich, 1998). 
One potential mechanism is deletion or downregulation of death receptors. Therefore 
the surface expression of the different receptors was analyzed. In our study, however, 
the CD95 surface expression of HTLV-1 infected T cell lines was not altered. Therefore 
resistance towards CD95-mediated apoptosis is not due to reduction of CD95 surface 
expression (Fig 3.3). Both, HTLV-1 infected and control T cell lines expressed various 
TRAIL receptors. As shown in Fig. 3.4, TRAIL-sensitive Jurkat and CEM T cell lines 
express both TRAIL receptors, TRAIL-R1 and -R2. However, the TRAIL-resistant HTLV-
1 infected T cell line MT-2, also expressed both TRAIL receptors. Therefore, resistance 
towards TRAIL-induced apoptosis was not due to reduction of TRAIL-receptor surface 
expression. Since sensitivity can be also mediated by upregulation of TRAIL decoy 
receptors, surface expression of decoy receptors Dc-R1 and Dc-R2 was analyzed. 
Decoy receptors are believed to negatively regulate TRAIL-induced apoptosis by 
competing for ligand binding (Sheridan et al., 1997). The TRAIL-resistant HTLV-1 
infected T cell line CHAMP expressed decoy receptor Dc-R2. However, the TRAIL-
sensitive Jurkat T cell line also expressed one of the decoy receptors, Dc-R1.  
Therefore, no correlation between expression of decoy receptors and resistance towards 
TRAIL-induced apoptosis was found. Taken together, it is unlikely that apoptosis 
resistance is mediated at the receptor level. Although it could not be excluded that death 
receptors in HTLV-1 infected T cells were mutated at the ligand binding site or were 
truncated in their signaling transduction domain. Since the glycosylation status of cells 
has been shown to modulate their sensitivity towards death receptor-mediated 
apoptosis, the difference in sensitivity might also be mediated by differences in the 
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glycosylation status of the receptors (Peter et al., 1995).  
Apoptosis resistance in HTLV-1 infected T cells has been partly explained by increased 
expression of anti-apoptotic proteins involved in the intrinsic cell death pathway. Bcl-XL 
has been reported to be induced by Tax and Bcl-2 was highly expressed in HTLV-1 
infected T cells independently of Tax (Mori et al., 2001). The increased expression of 
Bcl-XL and Bcl-2 in HTLV-1 infected T cell lines has been confirmed in this study (Fig. 
3.5). However, Bcl-XL and Bcl-2 are mainly involved in the regulation of the intrinsic cell 
death pathway. So far, at the DISC, c-FLIP is the only protein known to inhibit CD95L- 
and TRAIL-induced apoptosis by preventing the activation of pro-caspase-8 (Fig. 4.1A). 
In our study we could show that HTLV-1 infected T cells expressed strongly elevated 
amounts of c-FLIP (Fig. 3.5; Krueger et al., 2006). Expression of Tax in an inducible 
system led to increased expression of c-FLIP and consequently, resistance towards 
CD95-induced apoptosis (Krueger et al., 2006). Downregulation of c-FLIP using siRNA 
abolished apoptosis resistance, thus, directly demonstrating the functional relevance of 
Tax-mediated upregulation of c-FLIP (Krueger et al., 2006). The expression level of c-
FLIP has also been shown to be critically involved in regulation of TRAIL-induced 
apoptosis (Mitsiades et al., 2002). This would suggest that HTLV-1 infected T cells were 
generally more resistant towards Death Receptor-mediated apoptosis due to the high c-
FLIP levels (Fig. 4.1B). 
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Figure 4.1: Mechanism of apoptosis resistance in HTLV-1 infected T cells 
towards CD95L and TRAIL.  
A) Pathway of Death receptor-mediated apoptosis induced by CD95L and TRAIL.          
B) HTLV-1 infected T cells express Tax which upregulates the anti-apoptotic proteins Bcl-
XL and c-FLIP. Bcl-XL inhibits apoptosis via the intrinsic cell death pathway, c-FLIP 
inhibits apoptosis via the extrinsic cell death pathway. 
 
In conclusion, Tax-mediated induction of c-FLIP protein provides an important 
mechanism by which HTLV-1 infected T cells escape CD95L- and TRAIL-induced 
apoptosis by the immune system. The important role of c-FLIP in tumorgenesis has also 
been demonstrated in other cancers e.g. Hodgkin lymphoma (Dutton et al., 2004).  In 
addition, it has been demonstrated in vivo that tumor cells with increased c-FLIP 
expression promote tumor establishment and progression by preventing death receptor-
induced apoptosis (Mathas et al., 2004). Furthermore, it has been shown that c-FLIP 
overexpression plays a role in resistance towards treatment with chemotherapeutic 
agents (Wang et al., 2005; Longley et al., 2006). Therefore, c-FLIP is an attractive target 
in cancer therapy.  
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4.2  Sensitization of HTLV-1 infected T cells towards 
death receptor-mediated apoptosis by 
Rocaglamide 
Plant-derived substances play a major role in treatment of human diseases in Traditional 
Chinese Medicine. Plant extracts have been used in treatment of various diseases for 
over 3.500 years, It became clear in the 1950s that plant-derived compounds can also 
play an important role in treatment of cancers. With a random screening approach of 
several plant extracts, the plant genus Aglaia of the family Meliaceae has been found to 
be a source of potential pharmaceutic agents (Fig. 9; King et al., 1982). The active 
compounds isolated from leaves and flowers of this plant were derivatives of 
cyclopenta[b]benzofuran and were named rocaglamide derivatives (King et al., 1982).  
The therapeutic potential of rocaglamide derivatives in anti-cancer treatment has been 
demonstrated in xenograft mouse models. Three of the lead rocaglamide derivatives, 
rocaglamide (Fig 1.10 nr. 1), silvestrol (Fig. 1.10 nr. 8), and 4’-demethoxy-3’,4’-
methylenedioxy-methyl rocaglate (Fig. 1.10 nr. 30) were tested in in vivo models using 
the human prostate cancer cell line PC3 (Hwang et al., 2004) and the human breast 
cancer cell line BC1 (Lee et al., 1998), respectively. Both studies showed that the growth 
of both cancer cells was delayed after treatment without signs of toxicity. In another 
study aglaiastatin exhibited tumor selectivity in vitro and had high anti-tumor activity 
against the SW480 and HT29/H11 colon carcinoma cell lines but not against the normal 
intestinal epithelial cell line IEC18 (Hausott et al., 2004). The tumor selectivity in vitro 
was also observed for the rocaglamide derivative rocaglaol (Fig. 1.10 nr. 27). The 
inhibition of cell proliferation in three tumor cell lines, Lu1, LNCaP, and MCF-7, was over 
three-hundred-fold higher as in normal human umbilical vein endothelial cells (HUVEC) 
indicating a potential tumor selective property (Kim et al., 2006).  
Recently, studies of our group demonstrated that rocaglamide derivatives do not only 
excert cytostatic activity but also have a cytotoxic effect, by inducing apoptosis in 
leukemia cell lines and leukemia cells derived from patients. Importantly, rocaglamide 
derivatives do not show substantial toxicity against normal peripheral blood lymphocytes 
isolated from healthy donors (Zhu et al., 2007, Fig. 3.9; 3.10). 
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In this study we further investigated the mechanism of action of Rocaglamide 
derivatives. Therefore, the effect of one of the derivatives, Roc-AR was tested in CD95L 
and TRAIL resistant HTLV-1 infected T cells. HTLV-1 infected T cells were sensitive 
towards apoptosis only at a low percentage at a dosis of 100 nM Roc-AR (Fig. 3.22). 
However, treatment by Roc-AR with CD95L or TRAIL in combination resulted in a 
significant increase in apoptosis, which was demonstrated by DNA fragmentation, 
increased  activation of caspase-8, the main caspase involved in receptor-mediated 
apoptosis, and the activation of the executing caspase-3 (Fig. 3.7; 3.8; 3.9). The effect of 
Roc-AR in combination with CD95L or TRAIL was rather synergistic than additive. 
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4.3  Molecular mechanims of Roc-induced 
sensitization of receptor-mediated apoptosis 
Previous findings have shown that certain drugs can result in the upregulation of CD95 
or TRAIL receptor expression and thereby sensitize cancer cells towards apoptosis. For 
example, it was shown that treatment of hepatoma cell lines with the proteasome 
inhibitor MG132 lead to upregulation of TRAIL-R2 (Ganten et al., 2005). Several anti-
cancer drugs cause up-regulation of CD95 (Woo et al., 2004). Therefore, the receptor 
expression levels of Roc-AR-treated cells were examined. However, the surface 
expression of the death receptors (CD95, TRAIL-R1/R2) and decoy receptors (Dc-R1 
and Dc-R2) were not affected by Roc-AR treatment (Fig. 3.11, 3.12). As receptor 
surface expression was not altered by Roc-AR treatment, it was likely that Roc-AR-
induced sensitization does not occur at the receptor level. Therefore we analyzed the 
apoptotic signaling pathway downstream of the receptors.  
As shown in our previous studies, resistance of HTLV-1 infected T cells to CD95-
induced apoptosis was mediated by a high expression of c-FLIP protein (Krueger et al., 
2006; Fig. 4.2A). In this study, treatment with Roc-AR resulted in a strong decrease in c-
FLIP expression as early as 2 hr after exposure to Roc-AR (Fig. 3.13A; Fig. 4.2B). In 
contrast, the expression level of procaspase-8 was not altered after treatment with Roc-
AR. As c-FLIP is found to be the major inhibitory protein at the DISC level, 
downregulating c-FLIP expression is therefore considered to be the major event 
responsible for the sensitization of the infected T cell lines. However, Roc-AR is also 
affecting other anti-apoptotic proteins such as Bcl-xL and Mcl-1 which might also play a 
role in the sensitization towards CD95- and TRAIL-induced apoptosis (data not shown).  
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Figure 4.2: Mechanism of sensitization by Roc-AR of HTLV-1 infected T cells 
towards CD95-induced apoptosis. 
A) HTLV-1 infected T cells are resistant towards CD95L- and TRAIL-induced apoptosis 
by an increased expression of c-FLIP and Bcl-XL. B) Roc-AR decreases c-FLIP and Bcl-
XL expression and thereby sensitizes towards CD95L- and TRAIL-induced apoptosis. 
 
4.4  Molecular mechanims of Roc-mediated 
suppression of c-FLIP expression 
Next, the mechanism of the decrease in c-FLIP protein by Roc-AR was analyzed. 
Because our group previously showed that the Tax protein induced an increased 
expression of c-FLIP in HTLV-1 infected T cells (Krueger et al., 2006), the expression 
level of the Tax protein was analyzed after Roc-AR treatment. Roc-AR did not alter the 
Tax protein level for up to 32 hr of exposure to Roc-AR, whereas c-FLIP protein 
decreased already after 2 hr. Therefore, the Roc-mediated decrease in c-FLIP protein 
expression is independent of Tax protein expression levels, although the possibility that 
Roc-AR might interfere with Tax function cannot be excluded.  
Tax was reported to induce the transcription factors NFAT and NF-ĸB, which were both 
reported to be involved in the regulation of c-FLIP expression (Micheau et al., 2001; 
Kreuz et al., 2001). Previous studies showed that Rocaglamide derivatives can inhibit 
NF-ĸB and NFAT activity (Baumann et al., 2002; Proksch et al., 2005). Therefore, Roc-
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AR-mediated decrease in c-FLIP expression might be due to a Roc-mediated inhibition 
of NFAT and NF-ĸB activity. It was reported that NFAT was constitutively activated in 
HTLV-1 infected T cells (Good et al., 1996). However, a constitutive nuclear localization 
of NFAT could not be detected in the HTLV-1 infected T cell lines (Fig. 3.14A). In 
addition, cyclosporin A, a NFAT inhibitor, could not inhibit the high expression of c-FLIP 
in this study (Fig. 3.14B). This indicates that the decrease in c-FLIP protein expression is 
unlikely to be mediated by inhibition of NFAT activity. 
NF-ĸB was reported to be activated in ATL patients and also in various types of other 
malignancies, most frequently in hematopoietic malignancies such as chronic 
lymphocytic leukemia (Delic et al., 1998), multiple myeloma (Feinman., et al., 1999), 
Hodgkin disease (Bargou., et al., 1997), acute lymphoblastic leukemia (Kordes et al 
2001) and cutaneous T-cell lymphoma (Izban et al., 2000). The NF-ĸB inhibitor Bay 11-
7082 was shown to down-regulate the expression of the anti-apoptotic protein Bcl-xL 
(Fujii et al., 2002). Inhibition of the proteasome by PS-341 (bortezomib) inhibited the 
degradation of IĸBα and thereby inhibited NF-ĸB.  Both approaches lead to the induction 
of apoptosis in HTLV-1 infected T cells in vitro (Tan et al., 2002; Satou et al., 2004). 
Therefore, NF-ĸB is an attractive target for therapy. The constitutive activation of NF-ĸB 
was confirmed in the investigated HTLV-1 infected T cell lines (3.16A). In a previous 
study, the group of Proksch et al, claimed that Rocaglamide derivatives were potent NF-
ĸB inhibitors (Baumann et al., 2002). However, our studies showed that NF-ĸB activity is 
not affected by Roc-AR. First, Roc-AR had no effect on the nuclear localization of the 
NF-ĸB subunits p50 and Rel A (3.16B), second, the NF-ĸB inhibitor A-4-quinazoline, the 
activity of a luciferase reporter containing 4x NF-ĸB consensus sequence could not be 
inhibited by Roc-AR (data not shown). In the study of Baumann et al., the effect of 
Rocaglamide derivative Roc-B on inhibition of IĸB degradation was analyzed. However, 
our lab did not find any inhibitory effect on NF-ĸB activity for more than ten rocaglamide 
derivatives tested including Roc-B (diploma thesis, Zhu). There are also some critical  
data in the study by Baumann et al. First, inhibition of TNF- and PMA-induced IĸB 
degradation by Roc-B was only observed at 30 min whereas other time points were not 
affected. This cannot explain the sustained NF-ĸB inhibition shown in their study. 
Second, Baumann et al, showed that NF-ĸB inhibition by Roc-B could only be seen in 
the Jurkat cell line, stably transfected with a NF-ĸB reporter construct, but not by 
 
109
Discussion 
transient transfection of the NF-ĸB reporter plasmid into other cell lines. The authors 
explained such discrepancy by the hypothesis that NF-ĸB signal transduction cascades 
differ between T cells and other cell types. However, no evidence indicates that the 
kinases involved in signal transduction from the cell surface to the IKK complex are 
different between these cells. Furthermore, our lab could not detect an NF-ĸB inhibitory 
effect on Jurkat cells by transient transfection studies (data not shown).  
In contrast to Roc-AR, treatment of HTLV-1 infected T cells with A-4-quinazoline led to 
an inhibition of c-FLIP mRNA expression. This indicated that the decrease in c-FLIP 
expression after Roc-AR treatment is not regulated at the transcriptional level (Fig. 
3.17). After exclusion of transcriptional inhibition of c-FLIP by Roc-AR, the effect of Roc-
AR on protein synthesis was examined and compared with the well-known protein 
translation inhibitor cycloheximide (CHX). Roc-AR inhibited protein synthesis almost 
completely at a concentration of 100 nM for the analyzed period (Fig. 3.18). 
Interestingly, Roc-AR had no effect on protein translation in an in vitro system (Fig. 3.19) 
indicating that Roc-AR does not directly affect the translation machinery and instead, 
affects a signaling pathway required for translation.   
It has been shown that the PI3K/Akt signaling pathway was activated in HTLV-1 infected 
T cells. HTLV-1 Tax stimulates PI3K/Akt and the downstream target mTOR, leading to 
the activation of pro-survival signals in HTLV-1 infected T cells (Ikezoe et al., 2006). The 
effects observed with Roc-AR treatment could have been mediated by interfering with 
this pathway. Therefore the phosphorylation status of mTOR and the downstream target 
S6 after Roc-AR treatment was tested and compared with rapamycin, a well known 
mTOR inhibitor. Rapamycin blocked phosphorylation of mTOR and the downstream 
kinase S6 (Fig. 3.20A). Further, rapamycin inhibited the proliferation of HTLV-1 infected 
T cells to some extent (data not shown). However, the phosphorylation status of mTOR 
was not altered or even seemed to be increased after Roc-AR treatment (Fig. 3.20B). 
These results demonstrate that Roc-AR does not block the mTOR signaling pathway.  
Besides the PI3K/Akt/mTOR pathway, protein translation is also known to be regulated 
by the RAS-activated ERK signaling pathway. The ERK pathway has been implicated in 
several processes including the regulation of survival, angiogenesis and cell cycle 
(McKay and Morrison, 2007). The ERK pathway regulates protein translation via the 
phosphorylation of the kinase Mek1/2 which in turn phosphorylates the kinase Mnk1/2. 
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Mnk1/2 phosphorylates eIF4E which then has a higher affinity for the mRNA 5’ cap 
structure and thereby stimulates translation. Stimuli that increased the rate of protein 
synthesis generally increased the state of phosphorylation of eIF4E, and it was generally 
thought, that phosphorylation would activate eIF4E by increasing its affinity for capped 
mRNA (Raught and Gingras, 1999). Others suggested that the phosphorylation of eIF4E 
releases the binding from the 5’ cap structure once translation has been initiated to allow 
further binding of new ribosomes (Tuxworth et al., 2004). It has also been suggested 
that phosphorylation of eIF4E occurs later in the initiation process after recognition of the 
start codon. Phosphorylation of eIF4E could function to enhance the release of factors 
from the cap-structure, rendering the cap-binding factors available for the translation of 
different mRNAs. Our study showed that treatment with Roc-AR resulted in an inhibition 
of phosphorylation of MEK1/2, ERK1/2, Mnk1 and eIF4E which was detected as early as 
30 min upon exposure to Roc-AR (Fig. 3.21; Fig. 4.3). This indicates that Roc-AR affects 
protein translation by blocking the activity of the ERK pathway.  
Growth factor stimulation leads to activation of the ERK pathway which enhances 
synthesis of cyclin D1 and D2 and stimulates entry into the cell cycle (Vinals et al., 
1999). Conversely, stresses that reduce eIF4E availability and inhibit protein translation, 
leading to inhibition of the rate of synthesis of cyclin D1 and D2, and prevent cell cycle 
progression (Brewer et al., 1999; Hashemolhosseini et al., 1998). HTLV-1 infected T 
cells were reported to have an accelerated progression into S phase (Lemoine et al., 
2001). Furthermore, it was reported that cyclin D2 and to a lesser extend cyclin D1, were 
upregulated in HTLV-1 infected T cells. This was also confirmed by our study (Fig. 3.23).  
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Figure 4.3: Mechanism of Roc-AR induced cell cycle arrest and sensitization 
towards death receptor induced apoptosis. 
ERK phosphorylates the kinase Mnk1, which on its turn phosphorylates eIF4E. 
Phosphorylation of eIF4E increases its affinity for the 5’ cap structure and thereby 
stimulates translation. This leads to stimulation of cell proliferation and inhibition of 
apoptosis by upregulation of proteins as Cyclin D and c-FLIP. Treatment with Roc-AR 
results in a dephosphorylation of ERK, Mnk1 and eIF4E and blocks thereby cap-
dependent translation. This leads to a decrease in Cyclin D and c-FLIP expression and 
induces thereby a cell cycle arrest in G1-phase and sensitization towards death receptor 
induced apoptosis.  
 
 
 
112
Discussion 
Cyclin D1 and D2 are critical regulators of G1-S cell cycle progression in T cells, and 
dysregulation of cyclin D expression contributes to the aberrant cell growth of HTLV-1 
infected T cells. This study showed that Roc-AR decreased expression of cyclin D1 and 
D2, whereas the other cyclins remained unchanged (Fig. 3.23). This correlated with a 
G1 cell cycle arrest in all four HTLV-1 infected T cell lines (Fig. 3.22). The ERK pathway 
is crucial for cyclin D1 and D2 production and therefore provides a molecular link 
between this pathway and cell cycle control (Lavoie et al., 1999; Meloche and 
Pouyssegur, 2007). This is in agreement with our findings, which showed that the 
inhibition of this pathway leads to inhibition of cyclin D1 and D2 expression. Thus, 
inhibition of the ERK pathway by Roc-AR might be one of the important mechanisms by 
which Roc-AR inhibits c-FLIP expression and sensitizes towards death receptor-
mediated apoptosis and induces a G1 arrest by inhibiting cyclin D1 and D2 expression.  
4.5  Targeting the Raf-MEK-ERK pathway in cancer 
therapy 
The ERK signaling pathway is activated by several growth factor receptors e.g. the 
epidermal growth factor receptor (EGFR). Binding of its ligand causes the receptor to 
dimerize with a neighboring EGFR. The EGFR dimer serves as a docking place for the 
Grb2-SOS complex, which in turn activates Ras. Activated Ras binds Raf, which is 
activated through a process of phosphorylation at activation sites and dephosphorylation 
at inhibitory sites. Activated Raf subsequently phosphorylates and activates MEK1/2. 
Activated MEK1/2 in turn phosphorylates and activates ERK1/2 (McKay and Morrison, 
2007) (Fig. 4.4). The ERK pathway is aberrantly activated in cancer, particular by 
upstream activation of EGFR, the Ras small guanosine triphosphatases (GTPases) and 
Raf serine/threonine kinase isoforms (A-Raf-1, B-Raf, and C-raf). Mutations in the 
cytoplasmic kinase domain or truncations in the extracellular domain of EGFR are found 
in non-small cell carcinoma (NSCLC) (10%) and glioblastomas (20%) (Roberts and Der, 
2007). Mutations in Ras are found in pancreas cancer (90%), papillary thyroid cancer 
(60%), colon cancer (50%) and NSCLC (30%) (Downward, 2003; Roberts and Der, 
2007). Furthermore, B-Raf mutations are also found in a variety of solid tumor types, 
including melanoma (70%), papillary thyroid cancer (50%) and colon cancer (10%) 
(Brose et al, 2002; Roberts and Der, 2007). 
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Figure 4.4: Oncogene activation of the ERK pathway.  
Mutations in B-Raf, Ras, and the cytoplasmic kinase domain or extracellular domain of 
EGFR cause persistent activation of the ERK pathway in human cancers.  
 
Since the discovery that activating mutations of the ERK pathway are associated with 
human cancer, this pathway has been the focus of intense drug discovery effort. 
Inhibitors were developed several years ago against MEK1/2. PD98059 (Dudley et al., 
1995) and UO126 (Favata et al., 1998) are fairly specific, non-ATP-competitive MEK1/2 
inhibitors that have been widely used for research purposes. The inhibtor PD184352 has 
proven to be effective in inhibiting the growth of tumors in immunodeficient mice and has 
been used in a large study in colon carcinomas (Sebolt-Leopold et al., 1999). This drug 
has recently undergone Phase I clinical trials. It seems to be well tolerated at doses that 
inhibit ERK activation in patients’ peripheral-blood mononuclear cells. 
A variety of agents have been discovered that interfere with Raf activity, including 
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antisense oligonucleotides and small molecule inhibitors (Crooke, 2000; Lyons et al., 
2001). These inhibitors block the expression of Raf protein, the Ras/Raf interaction, or 
the Raf kinase activity. Sorafenib (BAY 43-9006) is the first oral multi-kinase inhibitor 
that targets the Raf kinases and recently entered phase III clinical trials (Lyons et al., 
2001). Pre-clinical studies showed that the drug has anti-tumor activity in vivo in 
xenograft models, and Phase I and II clinical trials revealed minor side effects such as 
diarrhea and skin irritation resulting from affecting cells with rapid turnover (i.e. in gut 
and skin). However, it has since been reported that Sorafenib might not be as specific as 
first thought and that it also interferes in other signaling pathways. Therefore the 
development of more specific inhibitors is necessary (Sebolt-Leopold and Herrera, 
2004).  Charaterization of the three-dimensional structures of the kinases Raf, MEK1/2 
and ERK1/2 will help to develop specific inhibitors. Also, detailed structural information 
on the binding modes of such inhibitors will significantly enhance the drug design 
process.  
In our study, we could show that Roc-AR blocked the phosphorylation of and thereby 
inactivated MEK1/2, ERK, Mnk1 and eIF4E. The remaining question still to be answered 
is what is the direct target of Roc-AR?  As dephosphorylation of MEK1/2 and ERK1/2 is 
observed, it could be that Rocaglamide derivatives directly target these kinases. Another 
possible target could be the p38 MAPK. In a previous study in our lab, it was shown that 
treatment of leukemia cells with Rocaglamide derivatives led to the activation of the p38 
MAPK pathway (Zhu et al., 2007). The pro-apoptotic  p38 MAPK pathway is activated by 
cellular stress, including UV light, arsenite, osmotic shock, and inflammatory cytokines 
(Ono et al., 2000). Recent findings indicate a requirement for a balance between 
MEK1/2, ERK1/2 and p38 signaling pathways to ensure appropriate regulation of cell 
survival (Ballif et al., 2001; Xia et al., 1995). It has been reported previously that 
activation of p38 MAPK inhibits the ERK1/2 signaling pathway via PP1/PP2A-dependent 
dephosphorylation of MEK1/2 (Westermarck et al., 2001). Furthermore, it was shown 
that inhibition of the ERK signaling pathway by p38 MAPK activation leads to initiation of 
apoptosis (Song-Ping et al., 2003). Therefore, inhibition of the ERK pathway could be 
regulated by a Roc-AR-mediated activation of p38 MAPK.  
Another possible target could be one of the upstream Raf kinases. Multiple signals 
converge to regulate Raf activation (Kolch, 2005). As shown in (Fig. 4.5), the major 
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activators of Raf kinases are the Ras small GTPases. Ras facilitates the plasma 
membrane association of Raf normally found in the cytosol. Additional signaling 
activities, including phosphorylation (of e.g., p21-activated protein kinases (PAK) 
serine/threonine and Src family tyrosine kinases) and dephosphorylation (of e.g. protein 
phosphatase 2A) events are required to fully activate Raf kinase function. Raf function is 
also regulated by interaction with other proteins, including 14-3-3 proteins and the 
chaperones, heat shock protein 50 and 90 (Hsp50/90). Another level of regulation of Raf 
involves the scaffold protein kinase suppressor of Ras 1 (KSR-1) that helps to regulate 
the activity, specificity and regulation of MEK/ERK signaling (Kolch, 2005). These 
multiple regulatory events suggest several possible targets for blocking the ERK 
pathway by Roc-AR.  
 
 
 
Figure 4.5: The Raf kinases are pivotal molecules within the ERK pathway, 
which regulate cellular proliferation and survival.  
Raf function is regulated by both positive and negative signal imputs. In particular, 
scaffold proteins, small GTPases, chaperones, kinases and phosphatases.    
 
 
Inhibitors of the ERK pathway can be classified as "cytostatic" rather than “cytotoxic” 
anticancer drugs (Downward, 2003). Such cytostatic agents may selectively inhibit the 
abnormal activation of their corresponding target molecule and suppress tumor cell 
growth without killing the tumor cells. This was observed with e.g. the MEK1/2 inhibitor 
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PD98059. Although treatment with this inhibitor completely suppressed the growth of 
tumor cells, it showed only a modest effect on induction of apoptosis (Hoshino et al., 
2001). Furthermore, since many inhibitors of this pathway are reversible, their removal 
would permit re-initiation of tumor cell proliferation. The majority of tumor cells after 
treatment with these inhibitors is in a "resting" state, but apoptosis is not initiated in the 
presence of such cytostatic inhibitors. However, a combination of MEK1/2 inhibitors and 
vincristine, for example, markedly enhanced the apoptosis-inducing activity of vincristine 
not only in tumor cells in vitro but also in human colon tumor xenografts in vivo (Sebolt-
Leopold and Herrera, 2004; Watanabe., et al 2002). Roc-AR displays not only cytostatic 
but also cytotoxic activity, which makes Roc-AR even more attractive as a therapeutic 
agent (Zhu, et al., 2007). This cytotoxic effect was also observed in this study, although 
at low amounts of Roc-AR, and the effect in HTLV-1 infected T cells was rather 
cytostatic. However, in combination with CD95L or TRAIL this cytotoxic effect is 
enhanced in a synergistic way. Therefore, as a therapeutic approach, since CD95 might 
be too toxic, combination therapy of Roc-AR with TRAIL is suggested. As discussed 
above, specific inhibition of the ERK pathway enhances the anticancer effect of a wide 
variety of cytotoxic chemotherapeutic agents (Dent and Grant, 2002). As a large number 
of ERK pathway inhibitors already entered clinical trials, there is considerable optimism 
that these inhibitors or new inhibitors such as Roc-AR in combination with targeting 
death receptor-mediated apoptosis will provide a new avenue of treatment. 
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ABBREVIATIONS 
 
4E-BP1 eIF4E-binding protein 
Ab antibody 
AICD Activation-Induced Cell Death 
AIDS Acquired Immunodeficiency Syndrome 
ALPS Autoimmune Lymphoproliferative Syndrome 
Apaf-1 apoptosis protease-activating factor 1 
APS Ammonium peroxidisulfate 
Asp Aspartate 
ATL adult T-cell leukemia/lymphoma 
ATP Adenosine triphosphate 
Bcl-2 B-cell lymphoma-2 
BH Bcl-2 homology 
bp Base pare 
caspase cysteine aspartate-specific protease 
CD cluster of differentiation 
CDK Cyclin-dependent kinase 
cDNA complementary desoxy-ribose-nucleic acid 
c-FLIP cellular FLICE-inhibitory protein 
CHX Cycloheximide 
CREB cAMP responsive element binding factor 
CsA Cyclosporin A 
DAG Diacylglycerol 
DD death domain 
DED death effector domain 
DISC death-inducing signaling complex 
DN Dominant negative 
DNA desoxy-ribose-nucleic acid 
DR death receptor 
DTT Dithiotreitol 
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ECL enhanced chemiluminescence 
eIF eukaryotic initiation factor 
ERK extracellular signal-regulated kinase 
FADD Fas-associated death domain protein 
FCS fetal calf serum 
FLICE FADD-like ICE 
FSC/SSC Forward Scatter, sideward scatter 
HAM HTLV-1-associated myelopathy 
hr hour 
HRP horseradish peroxidase 
HTLV Human T-Cell Leukemia Virus 
IAP inhibitors of apoptotic proteins 
IC50 Inhibitory concentration 50% 
ICE Interleukin-1β converting enzyme 
IEF Isoelectric focusing 
IgG Immunoglobulin G class 
IĸB Inhibitor of ĸB proteins 
IKK I-ĸB kinase 
IL Interleukine 
JNK c-Jun N-terminal Kinase 
kD Kilodalton 
LTR Long terminal repeat 
LZ Leucine-Zipper 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
Mcl-1 myeloid cell leukemia sequence 1 
MEKK1 MAPK/ERK Kinase Kinase 1 
min Minute 
Mnk1 MAP kinase interacting kinase 1 
mRNA Messenger ribonucleic acid 
mTOR mammalian target of rapamycin 
NFAT nuclear factor of activated T cells 
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NF-ĸB nuclear factor ĸB 
NGF Nerve growth factor 
NIK NFkB Inducing Kinase 
O/N Over night 
ORF Open reading frame 
PAGE Polyacrylamide gel-elektrophoresis 
PCR polymerase chain reaction 
PI Isoelectric point 
PI3K Phosphoinositide-3 kinase 
PMA phorbol 12-myristate 13-acetate 
PS Phosphatidylserine 
Roc-AR 
Rocaglamide derivative AR (oxo-11,12-methylendioxy-
rocglaol) 
RT Reverse Transcriptase 
RT room temperature 
RT-PCR Reverse Transkription Polymerase chain reaction 
SDS Natriumdodecylsulfate 
TCR T cell receptor 
TEMED Tetramethylethyl endiamin 
TNF Tumor Necrosis Factor 
TNF-R Tumor Necrosis Factor-Receptor 
TRAIL TNF-related apoptosis-inducing ligand 
TSP Tropical Spastic Paraparesis 
U Unit 
UV Ultraviolet 
V Volt 
v-FLIP Viral FLICE-inhibitory protein 
WB Western blot 
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